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Abstract.
Recurrent melioidosis represents relapse following failure to eradicate bacteria 
responsible for the primary infection or re-infection with a new strain. The first results 
chapter (chapter 3) evaluates the proportion of recurrent melioidosis due to relapse 
versus re-infection. Isolates from the same patient with an identical genotype were 
considered as relapse and those with a different genotype as re-infection. Three quarters 
of recurrent cases were due to relapse and one quarter were due to re-infection. There 
are two ways in which this approach could be confounded. First, ‘re-infection’ could 
actually represent relapse if primary infection was caused by simultaneous infection 
with multiple B. pseudomallei strains, followed by chance selection of different strains 
from the two episodes for genotyping. The chance of this mistake occurring is based on 
the rate of polyclonal B. pseudomallei infection. Chapter 4 describes the rate of 
polyclonal infection in a large group of unselected patients in northeast Thailand, which 
was very low (2/133 cases, 1.5%). Second, ‘relapse’ could actually represent re­
infection in the event that re-infection was caused by a B. pseudomallei strain that was 
by chance identical to the primary strain. The probability of this happening is based on 
the degree o f genetic diversity o f B. pseudomallei in the environment. Chapter 5 
demonstrates that the population of B. pseudomallei in even a small sampling site is 
extremely diverse. Thus, it is unlikely that the assessment of the causes o f recurrent 
melioidosis contained significant errors due to polyclonal infection or low genetic 
diversity of the organism. Chapter 6 examines specific risk factors of relapse and re­
infection. Duration and choices of antibiotics used for the primary episode were major 
determinants of relapse. Chapter 7 compares the clinical manifestations of relapse and 
re-infection and develops a simple scoring index to predict relapse or re-infection in 
patients presenting with recurrent melioidosis.
xvii
Chapter 1. Introduction.
1.1 General background.
1.1.1 The genus Burkholderia.
Burkholderia spp. are glucose non-fermenting Gram-negative bacilli that were 
formerly classified within the genus Bacillus, Malleomyces and Pseudomonas, only to 
be regrouped as a new genus in 1992 (271). The genus Burkholderia contains over 30 
species, which occupy remarkably diverse ecological niches ranging from soil to the 
human respiratory tract (58). Burkholderia thailandensis and Burkholderia 
pseudomallei are saprophytes, and both may be isolated from the same 
environment.(236). The Burkholderia cepacia complex is ubiquitous in nature and can 
be found in soil, water (including sea water), the rhizosphere of plants, in humans and 
various animal species and even in the hospital environment.
Some Burkholderia species are plant pathogens (58). Burkholderia caryophylli 
is pathogenic for carnations (Dianthus caryophyllus) and causes onion rot. 
Burkholderia plantarii causes seedling blight of rice and forms a disease-causing 
aromatic compound. Burkholderia glumae causes rot of rice grains and seedlings. 
Burkholderia andropogonis is the causative agent o f stripe disease of sorghum 
{Andropogon sp.), and leaf spot of velvet bean (Stizolobium deeringianum). By 
contrast, several Burkholderia  species have beneficial interactions with plants and 
colonize roots, stems and leaves. Burkholderia vietnamiensis and Burkholderia 
kururensis act as N 2-fixing bacteria for maize and coffee plants (87). Burkholderia 
tuberum  and Burkholderia phymatum  are involved in nitrogen fixation and nodulation 
in tropical legume plants.
There are three important human pathogenic species. These are Burkholderia 
mallei which causes glanders, Burkholderia pseudomallei which causes melioidosis,
and Burkholderia cepacia which is a cause o f pulmonary infection in patients with 
cystic fibrosis. A phylogenetic tree based on recA sequences of the genus Burkholderia 
is presented in figure 1-1 (170).
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Figure 1-1. The phylogeny of the Burkholderia genus.
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1.1.1.1 Burkholderia pseudomallei.
B. pseudomallei is a Gram-negative, aerobic, non-spore-forming, facultatively 
intracellular, oxidase-positive motile bacillus. This bacterium is the causative agent of 
melioidosis and is classified as a Hazard Group 3 pathogen by the Centers for Disease 
Control (CDC), United States. In clinical material, Gram staining may be irregular, and 
bipolar staining may be seen. B. pseudomallei accumulates polyhydroxybutyrate (PHB) 
in large, central granules to give a negative staining effect on Gram stain. However, this 
appearance is not specific to Burkholderia and may be absent in young colonies. The 
accumulation of prominent granules of PHB as an energy store reflects a metabolism 
adapted to long-term survival (109). The bacilli usually appear singly but may be in 
long bundles. During environmental sampling, B. pseudomallei can be distinguished 
from the closely related but less pathogenic B. thailandensis by the ability of the latter 
to assimilate L-arabinose (205). The genome sequence of B. pseudomallei strain 
K96243 from Thailand was completed in 2004. This demonstrated that B. pseudomallei 
contains many genes that promote survival in diverse and challenging environments 
and a large selection of genes that modulate pathogenicity and host-cell interactions 
(109).
1.1.1.1 Burkholderia mallei.
Burkholderia mallei is a non-motile, usually oxidase-negative, Gram-negative 
bacillus that has been classified as a Hazard Group 3 pathogen. The bacilli may be 
arranged singly, in pairs end to end, in parallel bundles or palisades. B. mallei is a host- 
adapted pathogen that does not persist in nature outside of its host. It is an obligate 
parasite of horses, mules, and donkeys with no other known natural reservoir. This 
organism is the causative agent of glanders (212), which is one of the oldest diseases 
known to man and was first described by Aristotle (384-322 before Christ) (165).
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Glanders is an abscess-forming infection of horses and other equines, which 
occasionally affects humans with occupations involving close contact with infected 
animals. In humans, glanders is characterized by pustular skin lesions, signs of sepsis, 
pneumonia and either necrosis of the tracheobronchial tree if the organism was inhaled, 
or multiple abscesses if  the skin was the portal of entry. Glanders was eradicated from 
North America in the 1930’s and is very rare today. There is evidence that B. mallei 
was also used as a biological weapon (254). The complete genome sequence of B. 
mallei strain ATCC23344 was published in 2004. This identified that major genetic 
adaptation had occurred in association with a putative shift from soil saprophyte to a 
highly specialized obligate mammalian pathogen (165). The major genetic feature was 
genomic downsizing. Whole genome sequence confirmed a previous suggestion based 
on multilocus sequence typing (MLST) that B. mallei has evolved from a clone of B. 
pseudomallei (98).
1.1.1.3 Burkholderia cepacia.
Burkholderia cepacia was discovered from rotting onions by W alter Burkholder 
in 1949. However, it is now considered by agricultural microbiologists as an agent that 
promotes crop growth (59). B. cepacia is motile by virtue of polar flagella. It is found 
in soil, water and on plants, and can survive longer in wet environments than in dry 
ones. B. cepacia has been used as a biocontrol agent as it is not toxic, does not pollute 
water or soil, can degrade unwanted chemicals and produces multiple antibiotics 
against fungi that are pathogenic for plants (111). After widespread usage, this 
organism was found to be a human pathogen. It was first detected in cystic fibrosis 
patients in 1971 (112). B. cepacia is now recognized as an important opportunistic 
pathogen in the hospital setting and an important pathogen in cystic fibrosis patients 
(101). Cystic fibrosis patients who acquire B. cepacia may follow one of three different
5
clinical courses: persistent colonization without alteration of lung function, 
significantly accelerated reduction of lung function, or rapid deterioration with acute 
necrotic pneumonia and fatal outcome within several weeks or months, which has been 
termed cepacia syndrome (124).
1.1.1.4 Burkholderia thailandensis.
Burkholderia thailandensis was first recognized in 1997 as a non-virulent 
biotype of Burkholderia pseudomallei that was distinguishable from a virulent biotype 
by the ability to assimilate arabinose (205). B. thailandensis is Gram-negative, motile, 
and has two to four flagella. B. thailandensis has similar morphology and antigenicity 
to B. pseudomallei. The API20NE and API50CH biochemical profiles used to 
differentiate glucose fermenting Gram negative bacteria give similar profiles for B. 
thailandensis and B. pseudomallei (267). These two species also react similarly in the 
indirect haemagglutination assays (IHA) used for melioidosis serology (267). 
Lipopolysaccharide (LPS) from B. thailandensis and B. pseudomallei is also 
immunologically indistinguishable (8). However, the virulence of these two organisms 
is totally different; the 50% lethal dose (LD5o) for B. thailandensis was reported to be 
109 CFU/mouse, compared with 182 CFU/mouse for B. pseudomallei (205). B. 
thailandensis may also be found in large quantities in the environment in the same soil 
or water as B. pseudomallei (236). Approximately 25% of soil isolates from northeast 
Thailand are culture positive for B. thailandensis (267). Colonial morphologies of both 
species grown on the same selective agar may be difficult to distinguish. A latex 
agglutination test based on a monoclonal antibody to B. pseudomallei 
exopolysaccharide (EPS) can be used to rapidly differentiate B. pseudomallei and B. 
thailandensis (positive for B. pseudomallei but negative for B. thailandensis) (262). 
Only 2 cases of infection by B. thailandensis have been reported. The strain from the
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first case report was lost and cannot be re-evaluated (144). The other case reported in 
the US was 2-year old boy with pneumonia and bacteraemia caused by B. 
thailandensis. This patient was pulseless and apneic following a road traffic accident in 
which he was immersed in water for 2 minutes (95). The complete genome sequence 
of B. thailandensis strain E264 was published in 2005. This suggested that divergent 
evolution o f a small set of genes was associated with the development of different life 
styles among B. thailandensis, B. pseudomallei and B. mallei (134).
1.1.2 Bacteriology of B. pseudomallei.
1.1.2.1 B. pseudomallei as an environmental saprophyte.
B. pseudomallei is commonly found in water and soil in melioidosis-endemic
\
areas including northern Australia and Southeast Asia, and is occasionally found in 
other tropical areas of the world (33). B. pseudomallei has the unusual ability to survive 
for months to years in the environment throughout the dry season (233) and in water in 
the absence of nutrients (269). Bacterial counts of B, pseudomallei in soil have been 
shown to be related to the risk of developing melioidosis (206). B. pseudomallei 
contaminating a community water supply has been reported to have caused two 
outbreaks o f melioidosis (70; 122).
Periodic soil sampling for B. pseudomallei has shown that the persistence of 
culturable bacteria depends on soil type and hydration (233). Well drained, light, sandy 
soils are less able to support the persistence o f B. pseudomallei, while waterlogged, 
heavy clay soils are much better at supporting bacterial persistence (123). The optimal 
temperature and pH for B. pseudomallei is 24°C to 32°C and 5 to 8 , respectively (235). 
Soil with a water content of less than 10% led to the death of B. pseudomallei within 70 
days, while soil with a water content o f more than 40% supported the persistence of B. 
pseudomallei for more than 2 years (235). Soil samples taken from a depth greater than
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30 centimeters were more likely to contain B. pseudomallei compared with the surface, 
reflecting a preference for higher moisture content and lower temperature (233;268). 
Samples recovered from a soil depth of 90 cm in Thailand yielded up to 105 CFU B. 
pseudomallei per gram of soil (206). A rising water table in the tropical rainy season 
has been proposed as one explanation for the reappearance of B. pseudomallei in the 
superficial layers of soil. There is a strong association between monsoonal rains, 
occupational exposure to surface water and mud, and the incidence of B. pseudomallei 
infection (67;222).
1.1.2.2 B. pseudomallei genome.
The published genome of B. pseudomallei strain K96243 contains two 
chromosomes of 4.07 megabase pairs and 3.17 megabase pairs, respectively (109). The 
large chromosome encodes many core functions associated with central metabolism 
and bacterial growth. The small chromosome carries more genes associated with 
adaptation and survival in different niches. The G+C content is 68%. A summary o f the 
key genes identified is listed in table 1- 1.
Table 1-1. Genes associated with survival and virulence functions encoded by the 
B. pseudom allei genome.
Survival
Secondary metabolism Possible antibiotic, surfactant and siderophore 
biosynthesis pathways
Drug resistance Ambler class A, B, and D p-lactamases, including 
cephalosporinase and oxacillinase; multidrug efflux 
systems, including aminoglycoside-, macrolide-, and 
polymyxin p-specific systems; aminoglycoside 
acetyltransferase
Intracellular stress Superoxide and nitric oxide detoxification
M otility and chemotaxis Flagellar system, chemotaxis-associated proteins
Virulence
Secretion Type I, type II, type III, and type V protein secretion 
systems, including three type III secretion systems
LPS and capsule Capsular polysaccharide synthesis and export 
cluster; LPS biosynthesis cluster.
Exoproteins Phospholipases C, metalloprotease A, and other 
proteases and collagenases
Adhesins Surface proteins potentially modulate host-cell 
interactions
Fimbriae and pili Type I fimbriae, type IV pili and tad-type pili
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Genomic islands are likely to represent DNA that has been recently horizontally 
acquired and are variably found in clinical and environmental strains of B. 
pseudomallei. Approximately 6% of the B. pseudomallei genome is made up of 
putative genomic islands (109). These are mostly absent from the B. thailandensis and 
B. mallei genomes. Gene deletion may have accounted for their absence in B. mallei, 
possibly as a result of mammalian host restriction and the associated change in 
selective pressure (165).
1.1.2.3 Virulence factors of B. pseudomallei.
B. pseudomallei is a facultative intracellular pathogen which can invade and 
survive in eukaryotic cells, even in phagocytes (180). After internalization, B. 
pseudomallei can escape from a membrane bound phagosome into the cytoplasm (127). 
This is followed by actin polymerization and the formation of membrane protrusions at 
one pole, a process that mediates cell-to-cell spread of the organism (216). B. 
pseudomallei also has the ability to induce cell fusion and multinucleated giant cell 
formation, and the ability to induce apoptosis in both phagocytic and nonphagocytic 
cells (132). These characteristics may be important in human infection and virulence. 
Additional putative virulence factors for infection are quorum sensing, capsular 
polysaccharide and pili, LPS and the ability to form biofilm.
1.1.2.3.1 Quorum sensing.
This term describes the ability by bacteria to communicate and display 
coordinated behaviour through the effect of a secreted signaling molecule. Quorum 
sensing networks, often o f a highly complex nature, have been identified in numerous 
Gram-negative bacterial pathogens. B. pseudomallei has been reported to co-ordinate 
gene expression through the expression of an V-acyl-homoserine lactone (AHL) (237).
10
Disruption of the operon encoding its expression led to a significant increase in LD50 in 
hamsters after intraperitoneal challenge, and an increase in time to death and decrease 
in organ colonization after aerosolized challenge (237). These findings suggest that 
quorum sensing plays an important role in virulence.
1.1.2.3.2 Type III secretion system.
B. pseudomallei contains three type III secretion system (TTSS) gene clusters 
(109). One o f these clusters (TTSS3 cluster) shares homology with the Inv/Mxi/Spa- 
like type III secretion gene cluster described for Salmonella enterica serovar 
Typhimurium and Shigella flexneri. The related type III secretion gene cluster in B. 
pseudomallei is termed bsa (Burkholderia secretion apparatus) (216). bsa encodes 
proteins that are very similar to S. typhimurium and S. flexneri secreted proteins 
required for invasion, escape from endocytic vacuoles, intercellular spread and 
pathogenesis. After bacteria escape from endocytic vacuoles into the cytoplasm of 
infected cells, membrane protrusions are formed through the action of actin 
polymerization at one pole. This facilitates cell-to-cell spread of bacteria without 
exposure to antimicrobials or immunoactive molecules. M utant strains lacking 
components of the Bsa secretion and translocation apparatus exhibited reduced 
replication in murine macrophage-like cells, an inability to escape from vacuoles and a 
complete absence of formation o f membrane protrusion and actin tails (216).
1.1.2.3.3 Capsular polysaccharide.
B. pseudomallei produces an extracellular capsular polysaccharide with the 
structure -3)-2-0-acetyl-6-deoxy-p-D-raflwzo-heptopyranose-(l- (186;215). Previously 
characterized as type I O-polysaccharide o f B. pseudomallei, this has more recently 
been considered to be a capsular polysaccharide based on its high molecular mass and
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genetic homology with group 3 capsular polysaccharides of other organisms. Capsular 
polysaccharide is required for B. pseudomallei virulence in experimental animal models 
(17; 186). Capsule expression is induced in the presence of serum, and the addition of 
purified B. pseudomallei capsule to serum bactericidal assays increased the survival of 
B. pseudomallei SLR5, a serum sensitive strain, by 1,000-fold (187). Phagocytosis was 
greater for a capsule-deficient mutant compared to wild-type in the presence of normal 
human serum (187). Both observations can be explained by the finding that deposition 
of complement factor C3b on the bacterial cell surface is lower in the presence of 
capsule (187). The capsule may act as a barrier, blocking access of the complement 
receptor-1 (CR1) on phagocytes to the C3b deposited on the bacterial surface (187).
1.1.2.3.4 Lipopolysaccharide.
B. pseudomallei lipopolysaccharide (LPS, formerly termed type II O-antigenic 
polysaccharide) appears to differ in several respects from the LPS of other Gram- 
negative organisms. B. pseudomallei LPS exhibits weaker pyrogenic activity in rodents 
compared with enterobacterial LPS, but stronger mitogenic activity in murine 
splenocytes (156). LPS-mediated activation of a mouse macrophage cell line in vitro is 
slower for LPS from B. pseudomallei compared with LPS from E. coli (238). B. 
pseudomallei LPS appears to be largely conserved across this species. LPS profiling of 
>700 B. pseudomallei isolates using proteinase K digestion and SDS-PAGE silver- 
stained gels, a technique that examines the O-side chain, demonstrated that the majority 
had a ‘typical’ ladder pattern of extracted LPS, 3% had an .‘atypical’ pattern, and 0.1% 
do not exhibit a ladder appearance at all (7). The different LPS preparations had similar 
endotoxic activity in the Limulus amebocyte lysate assay. However, there appears to be 
a difference in the host immune response to these molecules as there is a lack of 
immunological cross reactivity on W estern blot between typical and atypical LPS using
12
patient sera infected with typical and atypical LPS isolates (7). LPS of B. pseudomallei 
and B. thailandensis have been compared. LPS profiling using proteinase K digestion 
and SDS-PAGE silver stained gel demonstrated identical ladder patterns for the 
majority of isolates of both species. The two species exhibited similar immunoblot 
profiles against pooled sera from patients with melioidosis, and with hyperimmune 
mouse sera (8). LPS shedding profiles are also similar between the two species (10). 
This has led to the suggestion that LPS is unlikely to be involved in the virulence and 
pathogenicity of B. pseudomallei (8). Other possible explanations are that: (i) LPS from 
the two species are antigenically very similar but differ in biological activities, or that 
(ii) LPS from both species have biological activity in vivo, but only B. pseudomallei has 
an additional complement of genes that promotes successful invasion and bacterial 
dissemination within the host.
1.1.2.3.5 Biofilm.
B. pseudomallei can form  a film at the air-liquid interface of a laboratory culture 
after incubation at 37°C for 24 hours. Biofilms contain slowly growing bacteria and 
extracellular polysaccharide in complex three-dimensional structures (207). Slow- 
growing bacteria within the film are inherently more resistant to the action of 
disinfectants and antibiotics (246). The quantity of biofilm produced by B. 
pseudomallei has been reported to be higher than that of B. thailandensis (229). No 
difference was seen in the LD50 values in BALB/c mice between biofilm-deficient 
mutant and wild type, indicating that this is not a virulence determinant in this model 
(229), but this does not rule out a role for biofilm during human disease. Indeed, the 
development of biofilm in vivo could go some way to explaining the reason why even 
prolonged antibiotic treatment o f human melioidosis may fail to eradicate B. 
pseudomallei and resolve infection.
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1.1.2.3.6 Flagella.
B. pseudomallei is flagellated and motile. The ability of B. pseudomallei to 
invade and replicate in human lung cells in vitro was not different between wild-type 
and an isogenic mutant defective in flagella expression (53). In one study, there was no 
difference between an isogenic mutant and wild-type B. pseudomallei in diabetic rat 
and Syrian hamster infection models (79). In a second study, bacterial numbers were 
markedly reduced in the lung and spleen of BALB/c mice following intranasal infection 
with an aflagellate mutant compared with wild-type, and the mutant was less virulent 
following intraperitoneal infection of BALB/c mice as based on L D 5 0  (53).
1.1.2.3.7 Pili.
Adherence is an important virulence factor for bacteria and is mediated by 
carbohydrate molecules, pilus and non-pilus adhesins. The B. pseudomallei genome 
contains type IV pilin-associated loci, including a gene encoding a putative pilus 
structural protein (pilA). A pilA deletion mutant was shown to have reduced adherence 
to human epithelial cells and was less virulent in a nematode model and a murine 
model of melioidosis (86). This indicates a possible role for type IV pili in B. 
pseudomallei pathogenesis.
1.1.3 Bacterial genotyping.
A number of molecular typing methods have been used to investigate the 
epidemiology of B. pseudomallei, including ribotyping, random amplified polymorphic 
DNA (RAPD) analysis, pulsed field gel electrophoresis (PFGE) and MLST.
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1.1.3.1 Ribotyping.
Ribotyping is a fingerprinting technique targeting genomic DNA fragments 
containing all or part of the genes coding for 16S and 23S rRNA. This was originally 
developed by Stull et al. using an Escherichia coli rRNA probe to determine the 
molecular epidemiology of a range of Gram-negative organisms (218). In brief, 
chromosomal DNA is digested by restriction enzymes such as ZscoRI, HindlU, Sail, 
Pstl or BamHl. The resulting DNA fragments are separated by agarose gel 
electrophoresis, subjected to southern blot and hybridized with an rRNA gene probe. 
Hybridized fragments are visualized and the resulting banding pattern defined as a 
specified ribotype. Ribotype analysis for B. pseudomallei was developed in 1993 by 
Sexton et al. (198), in which DNA was digested using £<%>RI and the rRNA probe was 
based on E. coli. Ribotyping is a poorly discriminative technique for B. pseudomallei. 
For example, in one study conducted in the melioidosis-endemic northern territory of 
Australia, the majority o f isolates belonged to only three different BamHl ribotypes
(106). This compares with multiple genotypes based on either PFGE or MLST (34;36).
1.1.3.2 Random amplification of polymorphic DNA (RAPD).
RAPD analysis is a PCR-based method using a single short random primer that 
can anneal to multiple sites and which gives rise to multiple amplification products. 
PCR products are visualized using agarose gel electrophoresis. Differences in patterns 
are referred to as restriction fragment length polymorphisms (RFLPs). RAPD was 
developed for B. pseudomallei in 1995 (106). RAPD is less discriminatory than PFGE 
for several bacterial species (20; 136), and suffers from a lack of reproducibility 
between laboratories.
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1.1.3.3 Pulsed Field Gel Electrophoresis (PFGE).
PFGE is a genotyping method used to separate a small number of DNA 
restriction digest fragments to create a banding pattern of around 15-20 bands. Using 
standard gel electrophoresis, large DNA fragments (above 50 kb) migrate at similar 
rates, regardless o f size. By repeatedly switching the direction of the electric field, 
different sized fragments can be separated from each other. In this way, PFGE allows 
separation o f larger pieces of DNA than conventional agarose gel electrophoresis.
PFGE is one of the most commonly used typing tools for the study of bacterial 
epidemiology, and is particularly suited to short-term studies such as the outbreak 
setting.
Interpreting DNA fragment patterns generated by PFGE is important and 
guidelines proposed by Tenover et a l  are often used (230). Isolates that give identical 
results are classified as “indistinguishable” , rather than “identical” . A banding pattern 
difference o f up to three fragments can arise due to a single genetic event and thus these 
isolates are classified as “closely related”. Strains with differences of four to six 
restriction fragments are termed “possibly related”, and strains with more than seven 
restriction fragments different are considered “different”.
1.1.3.4 Multilocus sequence typing (MLST).
MLST is a molecular typing method based on the sequence comparison of 
seven conserved housekeeping genes (98). This has the advantage that the output is 
unambiguous and easily compared between laboratories. MLST has been described for 
a number o f important bacterial pathogens and has become an established technique for 
the precise characterization of isolates and for epidemiological studies. M LST has been 
developed for B. pseudomallei using the following genes: ace, gltB, gmhD, lepA, lipA, 
nark, and ndh. The different sequences at each of the seven loci are assigned different
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allele numbers and the series of seven integers that correspond to the allele numbers at 
the seven loci define the allelic profile of a strain. As examples, the allele profile 1-1-1- 
2-4-2-1 defines sequence type (ST) 1, and the allelic profile 1-1-13-1-1-1-1 defines 
ST10.
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1.2 Melioidosis.
The term ‘melioidosis’ was introduced in 1921 by Stanton and Fletcher (214). 
The name was derived from the Greek ‘m elis’ (meaning distemper of asses, which is 
usually taken to be glanders) and ‘eidos’ (meaning resemblance). M elioidosis is the 
most common cause of fatal community-acquired bacteraemia in northeast Thailand 
and bacteraemic pneumonia in the Northern Territory of Australia (67). In northeast 
Thailand, melioidosis accounts for 20% of all community-acquired bacteraemias, and 
causes death in 40% of treated patients (222). It mostly infects adults with an 
underlying predisposing condition, mainly diabetes mellitus and chronic kidney 
disease. Clinical manifestations of melioidosis are protean and have led to the term “the 
great mimicker” (273).
1.2.1 Geographical distribution of melioidosis.
The first case of melioidosis in humans was identified in Burma in 1911 (256). 
The post-mortem of an opium addict conducted by Captain W hitmore and his colleague 
Krishnaswami at Rangoon General Hospital demonstrated pathological features 
consistent with a “glanders-like” infection but the causative organism was noted to be 
motile, which was not consistent with glanders. The causative organism {B. 
pseudomallei) was described as a new species. A large outbreak of melioidosis was 
subsequently recognised in an animal facility in Malaya in 1913 (214). By 1917, 
Krishnaswami had reported over 100 human cases from Rangoon (139). Disease in 
humans and animals was subsequently reported in other areas of Southeast Asia, the 
region with most of the world’s cases (71). Sporadic cases were reported in the French 
military in Indo-China, and later in American military personnel returning from Burma 
and other regions in Southeast Asia during W orld W ar II. More than 150 cases of 
melioidosis occurred in U.S. soldiers involved in the conflict with Vietnam (116).
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Reactivation of disease (defined as recurrence of melioidosis some time after 
acquisition of the bacterium, which sometimes occurred in people with no recollection 
of a primary episode) in US military personnel many years after leaving the combat 
zone in Vietnam led to the introduction of the term the “Vietnamese time bomb” (100).
The first reported case of melioidosis in Thailand was in 1935 (48). W ith a 
growing clinical recognition and improvement in microbiology facilities, more than 
800 cases were reported by 1986 (128). The average annual incidence in northeast 
Thailand between 1987 and 1991 has been estimated to be 4.4 per 100,000 person- 
years (222). This disease is now considered an important occupational hazard in 
Thailand (234). In southern Thailand, melioidosis is not common and the bacterial 
concentration in soil specimens has been found to be lower compared with the 
northeast (206;247); however, melioidosis was identified in a number of tsunami 
survivors who aspirated and/or had lacerations during the 2004 tsunami (47;55). 
Melioidosis in travellers who visit Thailand or other melioidosis-endemic regions of 
Asia is also periodically reported (135; 151; 199).
The first reported human case of melioidosis in Australia was in, 1950 (191). 
Melioidosis is now recognized as the most common cause of fatal community-acquired 
bacteraemic pneumonia in the Northern Territory o f Australia (61). Occasional cases 
have been reported from Queensland, W estern Australia and Papua New Guinea (67). 
The highest incidence of disease is in the north of the Northern Territory and in the 
Torres Strait Islands adjacent to Papua New Guinea. A prospective study at the Royal 
Darwin Hospital during a 10 year period from 1989 to 1999 defined 252 melioidosis 
patients, giving an estimated average annual incidence of 16.5 per 100,000 (67).
North America and Europe are not melioidosis-endemic areas and cases there 
represent imported disease. An infection that occurred in an individual in Oklahoma 
following a farming accident was initially thought to be due to B. pseudomallei (270),
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but later proved to be caused by a novel species named Burkholderia oklahomensis 
(97). A true case o f melioidosis may have occurred in Georgia in association with a 
motor vehicle accident (167). Outbreaks of melioidosis in animals and two fatal human 
cases occurred in France in the mid-1970’s (71). The source for this outbreak may have 
been infected horses from Iran or a panda from China. An outbreak of melioidosis in 
animals was reported in Britain in 1992 following importation of an infected monkeys 
from the Philippines (74).
Central and South America have recently been recognized as melioidosis- 
endemic regions. M elioidosis has been reported in Martinque (169), Guadeloupe (173), 
and Puerto Rico (51;83). The Caribbean is also regarded as endemic for melioidosis 
(72). Melioidosis has been recognized as an emerging infectious disease in Brazil, 
where a cluster o f cases in Northern Brazil was associated with the onset of unusually 
heavy rainfall (194).
In the Indian subcontinent, sporadic cases of melioidosis have been reported 
from Sri Lanka, India, Pakistan and Bangladesh (21;130;172;217). In Africa, the 
epidemiology of melioidosis remains uncertain and is hampered by a lack of diagnostic 
facilities. Melioidosis has been described in a goat in Chad and in pigs in Niger 
(89; 179). Human melioidosis has also been reported from Uganda, Kenya and the 
Gambia (18;248).
1.2.2 Risk factors for melioidosis.
Risk factors for melioidosis have been evaluated by both case-control studies 
(220;222), and population based studies (69). Identified risk factors are summarized in 
table 1-2. An associated predisposition is present in 62% to 87% of patients with 
melioidosis (69;183;222).
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Table 1-2. Risk factors for melioidosis.
Risk factor Details
Male gender Males predominate in all case series, the ratio of males to females 
ranging from 1.4:1 in Thailand (222), 3:1 in northern Australia (66), 
3.2:1 in Malaysia (183), to 4.6:1 in Singapore (108).
Age Age > 45 years is an independent risk factor in northern Australia (RR 
4.0) (69), and incidence of melioidosis is highest in population aged 
40-59 years in Thailand (RR 4.1) (222).
Aboriginal
nationality
RR of 3.0 in northern Australia (69). This is assumed to be associated 
with environmental exposure associated with lifestyle.
Diabetes
mellitus
60% of patients in Thailand (222), 58% of patients in Singapore 
(108), 38% of patients in M alaysia (183), and 37% of patients in 
northern Australia (66) are diabetic, mainly type II.
Chronic lung 
disease
RR of 4.3 in northern Australia (69). This underlying condition has 
not been identified as a risk factor in Thailand.
Chronic 
kidney disease
RR of 3.2 in northern Australia (69) and OR of 2.9 in Thailand (220). 
In Thailand, chronic kidney disease included renal calculi, which 
were found in 8% of patients (222).
Alcohol excess RR of 2.1 in northern Australia (69). This was not reported in studies 
from Thailand (31;222), although 12% of melioidosis patients in 
Thailand had a history of heavy alcohol consumption (220).
Thalassemia OR of 10.2 in Thailand (220), including beta-thalassemia/hemoglobin 
E and hemoglobin H disease.
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1.2.3 Disease acquisition.
Melioidosis occurs as a result of exposure to environments containing B. 
pseudomallei. Acquisition occurs via inoculation, inhalation and ingestion. The major 
route of infection in farmers in northeast Thailand is likely to be contamination of 
existing wounds or new penetrating wounds with B. pseudomallei present in soil and 
water (222). Children infected with B. pseudomallei often have a history of repeated 
exposure to water and soil in rice fields (73). In Australia, aboriginals living in remote 
communities have frequent exposure to tropical soils and surface water through daily 
activities and hunting (69). Melioidosis in US helicopter crews and servicemen 
involved in the war with Vietnam is likely to represent infection via the respiratory 
route (90). An outbreak associated with contaminated drinking water (122) indicates 
that ingestion is an additional possible route, although this is probably rare. Near- 
drowning is also a known route of acquisition (222). This was highlighted by a cluster 
of melioidosis cases in PhangNga following the 2004 tsunami (47;55).
A case of mother-to-child transmission of B. pseudomallei has been reported 
(5). This involved a 31-year-old pregnant woman who was taking prednisolone for 
ulcerative colitis, which may have increased her susceptibility to infection. Identical B. 
pseudomallei isolates were obtained from both placenta and neonatal blood culture. 
Two cases o f transmission of B. pseudomallei via breast milk have also been described 
(185). Both lactating mothers had mastitis. In one case, B. pseudomallei isolated from 
breast milk and from the infant were identical on PFGE. Possible sexual transmission 
has also been reported between a Vietnamese veteran with prostatis and his wife (158). 
Person-to-person transmission may have occurred between a diabetic brother and sister 
living in endemic northeast Thailand (140), and between 2 siblings with cystic fibrosis 
in Australia (110). Suspected nosocomial melioidosis from hospital ground (15), 
contaminated of chlorhexidine-cetramide (S avion) (181) and contaminated hand wash
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detergent (94) have been reported. However, a direct cross-infection between hospital 
in-patients has not been reported in the published literature. Rare laboratory acquired 
infections have also been reported (102; 196).
1.2.4 Prevention of melioidosis.
Protective gear, including waterproof shoes or boots and protective gloves are 
recommended for agricultural workers in endemic areas. This is particularly pertinent 
to individuals at high risk of melioidosis. However, these are often uncomfortable when 
worn for prolonged periods in the heat of the tropics and are rarely used. The efficacy 
of this advice has not been evaluated for the prevention of melioidosis. People with risk 
factors for melioidosis should stay indoors during periods of heavy wind and rain due 
to the potential for aerosolisation of B. pseudomallei.
There is currently no vaccine available against melioidosis, although several 
groups are exploring potential vaccination strategies (163;253). In a mouse model, 
CD4+ T cells can mediate vaccine-induced immunity to experimental melioidosis
(107). Some protection has also been demonstrated in the mouse model following 
vaccination with B. thailandensis and other attenuated strains (119; 120). However, it 
may prove difficult to develop a protective vaccination for individuals living in highly 
endemic areas who are already antibody positive for B. pseudomallei.
1.2.5 Reactivation of melioidosis after latent infection.
Reactivation of latent infection (which is normally taken to mean clinical 
features of melioidosis in an individual previously exposed to B. pseudomallei but with 
no history of a primary episode, as opposed to relapse which is recurrent features in a 
person who has responded to treatment for a primary episode of melioidosis), is well 
recognized and led to concerns regarding soldiers returned from Vietnam and travellers
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exposed in endemic areas. The estimated number o f potential ‘cases’ (defined as the 
presence o f antibodies to B. pseudomallei) from the Vietnam W ar is around 250,000 
cases (56), while only a number of reactivated infections have been reported; latent 
periods of 26, 29, and 62 years have been documented (50; 157; 164).
In melioidosis endemic areas, reactivation of latent disease is presumptively 
diagnosed in patients admitted to hospital for an unrelated illness who subsequently 
develop melioidosis during admission, and who were previously asymptomatic but had 
pre-existing abnormalities such as an abnormal chest radiograph involving the same 
lung region. A prospective study in Australia reported that only 3% of patients were 
considered to have reactivation of latent infection rather than recent acquisition (64).
It is unclear whether high antibody titers in healthy individuals reflect quiescent 
foci. There is no evidence for a B. pseudomallei carrier state in humans, with recovery 
of the organism from a clinical specimen indicating active disease (129). The strong 
seasonal association of this disease and short incubation period suggests that primary 
disease occurs as a new infection rather than seasonal activation of a persistent focus. 
The other, less likely possibility is the seasonal development of underlying risk factors 
causing immune dysfunction, followed by seasonal activation.
1.2.6 Clinical manifestation of melioidosis.
1.2.6.1 Seasonal incidence of melioidosis.
M elioidosis is seasonal in the tropics where most cases present during the rainy 
season, which occurs between June and November in Thailand (222) and November to 
May in Australia (64). This can be explained by increased contact with the organism. 
Rice farmers plant at the start o f the monsoon and work in flooded rice paddies until 
harvest. Thai farmers rarely wear protective footwear and their feet often show signs of 
repeated trauma and injuries. Extreme weather may be associated with a shift in the
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mode of acquisition of infection. Aerosols are created during heavy rain, and this may 
result in repeated inhalation of the organism. Heavy rainfall and winds consistently 
result in a shift towards more pneumonia in patients presenting with melioidosis in 
Northern Australia (68).
1.2.6.2 Incubation period.
The period between B. pseudomallei exposure and onset of clinical features of 
melioidosis is highly variable and often difficult to define. A history of a specific 
inoculation event is often absent. In one study, 25% of cases reported a specific 
inoculation event from which an incubation period of 1-21 days (mean 9 days) was 
derived (67). The incubation period following aspiration may be very short, probably 
because the inoculum may be large and organisms gain direct access to a deep site (47). 
The incubation period may also be very prolonged (157), the maximum recorded being 
62 years (164).
1.2.6.3 Duration of symptoms.
The time from onset of disease to clinical presentation is highly variable. In 
northeast Thailand, around a third of patients have symptoms for less than 7 days, one 
half report being unwell for 7-28 days, and the remainder have symptoms for more than 
28 days (266). In Northern Australia, 13% of patients presenting for the first time had 
symptoms for more than two months (67).
1.2.6.4 Clinical syndromes.
Manifestations of disease are extremely broad and range from an acute 
fulminant bacteraemia to a chronic debilitating localized infection. Melioidosis is a 
great mimicker, and it is often impossible on clinical grounds to differentiate between
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melioidosis and other acute and chronic bacterial infections, including tuberculosis. The 
majority o f adult patients develop an acute septicaemia associated with bacterial 
dissemination that most commonly manifests as pneumonia and/or hepatosplenic 
abscesses. M ultiple organ involvement, and the development of additional organ 
involvement following presentation are also common (66).
1.2.6.4.1 Bacteraemia.
Bacteraemia is found in around half o f melioidosis patients in prospective 
studies: 46% in Australia (66), 59% in Malaysia (183), and 60% in Thailand (220). The 
lung is the commonest site of infection associated with bacteraemic melioidosis. 
Bacteraemia alone without localized organ involvement is also found (183). Septic 
shock with a brief incubation period is common and is frequently complicated by the 
development of irreversible organ damage and the multiple organ dysfunction 
syndrome. The mortality of melioidosis with septic shock varies from 60% in 
Singapore (22), 86% in Australia (66), and 90% in Thailand (38).
1.2.6.4.2 Lung involvement.
The lung is the most commonly affected organ and is involved in approximately 
half o f all cases, either presenting with primary pneumonia or lung abscess, or 
secondary to bacteraemic spread (blood-borne pneumonia). Sputum is often purulent 
but rarely blood-stained. Large or peripheral lung abscesses may rupture into the 
pleural space to cause thoracic empyema. The common radiographic patterns for acute 
pneumonia are localized patchy alveolar infiltrate, bilateral diffuse patchy alveolar 
infiltration or multiple nodular lesions consistent with haematogenous spread (188). 
Upper-lobe involvement with early cavitation and rapid progression are common.
Upper lobe infection in a patient with a subacute or chronic presentation can be difficult
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to distinguish from pulmonary tuberculosis on the basis of clinical features and 
radiological changes.
1.2.6.4.3 Liver and spleen involvement.
Solitary or multiple abscesses may develop in the liver and/or spleen. 
Hepatosplenic abscess is reported to be present in 28% of melioidosis patients in 
Thailand (201). This is the most common cause of pyogenic liver and splenic abscess in 
northeast Thailand (195;244). By contrast, hepatosplenic abscess was found in only 6% 
of melioidosis patients in Australia (66). Multiple abscesses are more common than a 
solitary abscess in both organs. The finding of a “Swiss cheese” appearance on 
ultrasonogram and “honeycomb” appearance on computed tomography (CT) scan are 
characteristic for melioidosis (11). More than half of patients with hepatosplenic 
abscess lack abdominal pain and abdominal tenderness (82). Spread of infection from a 
splenic abscess to the pleura, lung, adjacent stomach, liver, diaphragm and rib have 
been reported (226).
1.2.6.4.4 Genitourinary tract involvement.
Genitourinary infection is common in Australia, with prostatic abscesses 
occurring in 18% of male patients (66). A common clinical presentation of prostatic 
abscess is an obstructed urinary tract leading to urinary retention (225). On transrectal 
ultrasonogram, prostatic abscesses in patients with melioidosis are reported to appear 
alone or with hypo-echoic areas with internal septation, a thickened wall and 
surrounding multiple small daughter abscesses. Renal abscesses are often associated 
with calculi and urinary tract infection. Infection involving the urinary tract is present 
in at least one quarter of Thai patients based on a urine culture positive for B.
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pseudomallei, although only a quarter of positive cases had urinary symptoms such as 
urinary frequency, dysuria, haematuria, or flank or back pain (148).
1.2.6.4.5 Skin and soft tissue involvement.
Superficial pustules, subcutaneous abscesses and pyomyositis are common 
manifestations of melioidosis and may be the source of systemic infection, or may 
result from haematogenous or local spread. Skin and soft tissue infections are found in 
24% of melioidosis patients in Thailand (46) and 17% in Australia (66). Infection may 
run an aggressive course similar to that seen for necrotizing fasciitis caused by other 
organisms (252).
1.2.6.4.6 Neurological involvement.
Neurological melioidosis characterized by brainstem encephalitis and flaccid 
paraparesis is defined in 4% of melioidosis cases in northern Australia (33). Prominent 
features on presentation are unilateral limb weakness, predominant cerebellar signs, 
mixed cerebellar and brainstem features with peripheral weakness and flaccid 
paraparesis (65). Peripheral motor weakness may mimic Guillain-Barre syndrome (117) 
and unilateral limb weakness may mimic a stroke (137). Focal suppurative infections 
involving the central nervous system with or without meningitis have been reported. 
CNS infections occur in around 1.5% of melioidosis patients in Thailand, while the 
syndrome o f meningoencephalitis has not been defined in this setting (147). Early brain 
CT scan may be normal, but M RI often shows dramatic changes (65; 147).
1.2.6.4.7 Osteoarticular involvement.
Osteomyelitis and septic arthritis due to melioidosis have been reported and 
may be difficult to differentiate from other causes of infection, except that the systemic
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features of illness may be more prominent. Osteoarticular involvement was found in 
17% of melioidosis patients in Thailand (46) and 4% in Australia (66; 177). The knee is 
the most common site of septic arthritis (260). Osteomyelitis is often secondary to 
infection of another organ; however, localized osteomyelitis from B. pseudomallei has 
been reported (219).
1.2.6.4.8 Parotid gland involvement.
A unique syndrome of acute suppurative parotitis is present in around one-third 
of paediatric cases in Thailand (73), but this is uncommon in Thai adults and has been 
reported in one case from Australia (88). Infection is bilateral in 10% of patients, and 
may be complicated by rupture into the auditory canal, facial nerve palsy and 
necrotizing fasciitis (73; 146).
1.2.6.4.9 Other organ involvement.
Infections involving many other sites have been described, including 
lymphadenitis (49), mycotic aneurysm (150), adrenal gland abscess (142), mediastinal 
infection (189), pyoperdicarditis (145; 153), deep neck abscess (213), acute otitis media 
(257), sinusitis (146), corneal ulcers (204), orbital cellulitis (258), breast abscess (143), 
and scrotal abscess (125).
1.2.7 Diagnosis of melioidosis.
Melioidosis should be suspected in any severely ill febrile patient with an 
underlying predisposing condition who lives in, or has travelled from a melioidosis- 
endemic area. Evidence of pneumonia, abscess formation in the liver and spleen on 
ultrasound examination, soft tissue abscess and septic arthritis should be sought. The
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presence o f a splenic abscess in a person living in an endemic area is highly suggestive 
of B. pseudomallei infection.
The definitive diagnosis of melioidosis requires positive bacterial culture and 
identification. Microbiological culture should be performed on all available specimens 
including blood, urine, throat swab, respiratory secretions, pus and swabs from surface 
wounds. As B. pseudomallei is not a member of the normal flora and is not carried 
asymptomatically, a positive culture from any site is highly suggestive of infection. 
Because the organism can become disseminated in the host, the site of culture positivity 
may not necessarily reflect the major site of infection. For example, a positive throat 
swab may occur in a patient with a deep site abscess, and positive urine cultures may 
reflect spill over from the bloodstream as well as renal involvement.
The polymerase chain reaction (PCR) has been evaluated for the diagnosis of 
melioidosis but is not in routine use. A prospective unblinded evaluation in Australia 
that used primers targeting a region of the TTSS1 gene cluster demonstrated a 
sensitivity of 91% compared with standard culture for the diagnosis of melioidosis 
(160). However, a prospective blinded evaluation in Thailand using PCR primers 
targeting a region of the 16s rRNA gene showed a lower diagnostic sensitivity of 61% 
(25). Comparison of sensitivity of the assays using TTSS1 and 16s rRNA primers in the 
same population showed that the TTSS1 assay was inferior to 16s rRNA assay (23).
Serological diagnosis is possible in patients living in a non-endemic area who 
have not emigrated from an area of endemicity, but serology is not specific in 
melioidosis-endemic regions because the rate of background positivity in the healthy 
population is high (40). This is discussed in more detail in section 1.2.7.2 below. 
Clinical diagnosis is an imperfect strategy but is sometimes necessary when cultures are 
suspected to be falsely negative, or in settings where culture is not available.
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1.2.7.1 Laboratory identification of B. pseudomallei.
B. pseudomallei grows on most routine laboratory media (14). The organism 
exhibits considerable inter-strain and medium dependent variability in colonial 
morphology (78), and the wrinkled appearance o f older colonies has occasionally 
resulted in their being overlooked as contaminants. In specimens containing a mixed 
normal bacterial flora, B. pseudomallei may be overgrown by commensals and 
consequently overlooked. Several selective media have been developed to overcome 
this problem, the most widely used being A shdow n’s selective agar. This is a simple 
agar containing crystal-violet, glycerol and gentamicin. Mature colonies often take on a 
wrinkled appearance and take up crystal violet dye from the medium after several days 
of incubation, but some strains do not appear wrinkled. A recent study described and 
characterised seven colony morphology types for B. pseudomallei on Ashdown’s agar, 
type I (the wrinkled type) being the most common type found in clinical samples and 
the environment (24). Selective broth for the isolation of B. pseudomallei from clinical 
samples containing normal flora is also required to prevent overgrowth by other species 
(251). Use o f the selective broths significantly increases the frequency of isolation of B. 
pseudomallei over direct plating on Ashdown’s agar alone (265).
Laboratory identification of B. pseudomallei is a challenge to laboratories that 
are unfamiliar with the bacterium. The organism may be overlooked as “Pseudomonas 
spp.” . Biochemical markers of B. pseudomallei include a positive oxidase reaction, 
production o f gas from nitrate, arginine dihydrolase and gelatinaSe activities and 
oxidation o f a wide variety of carbohydrates. Common bacterial identification systems 
including the API20NE (bioMerieux), RapID (Remel) and the Vitek automated system 
are o f variable reliability for the identification of B. pseudomallei (96). B. pseudomallei 
can be misidentified as B. cepacia, Pseudomonas aeruginosa, Chromobacterium 
violaceum and a range o f other species. Latex agglutination using a specific
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monoclonal antibody to EPS is useful for the rapid identification of B. pseudomallei 
and differentiation from B. thailandensis (positive for B. pseudomallei and negative for 
B. thailandensis) (9). This assay has 100% accuracy for the rapid identification of B. 
pseudomallei Colonies growing on solid agar (81), but uses an in-house reagent which 
is not commercial available.
Direct immunofluorescent microscopy of infected sputum, urine, or pus is 98% 
specific and 70% sensitive compared with culture, and allows a diagnosis to be made 
within 10 minutes (249). Again, this uses an in-house reagent. Several PCR based 
techniques have been developed for the identification of B. pseudomallei (23;25;160), 
although these are not in routine use in the diagnostic laboratory setting.
1.2.7.2 Serological tests for B. pseudomallei.
Most healthy individuals (>80%) living in northeast Thailand develop 
antibodies to B. pseudomallei during childhood and some healthy individuals have very 
high titres (129;264), As a result, serological diagnosis has low specificity in 
melioidosis-endemic regions. Interpretation of serology is more straightforward in the 
non-endemic setting provided a knowledge of travel history and place o f normal 
residence is available. A rising antibody titre to B. pseudomallei in paired sera taken 
from an individual who does not normally reside in an endemic area supports the 
diagnosis of melioidosis in the presence of clinical features of disease.
Numerous reports have been published describing the use of IHA to define 
seropositivity in healthy populations and patients with culture-proven or suspected 
melioidosis. The diagnostic cut-off used to define a positive result has varied between 
studies; > 1 :10  has been used to define seroconversion in Thailand (32;264), and titres 
of > 1:16, 1:40 and 1:160 have all been used to define a diagnostic titre 
(12;13;108;261;272). The IHA test has poor diagnostic specificity in areas of high
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endemicity (12;261). Increasing the IHA cut-off leads to a rise in specificity but loss of 
sensitivity (166). The IHA is more useful in Singapore, where disease is sporadic and 
background seropositivity is <1% (108;272). Using a cut-off titre of 1:16, less than 1% 
of the asymptomatic population had a positive titre, while 20 patients with melioidosis 
had titres o f 1:16 or greater (108;272).
Several other tests have been described, including an indirect 
immunofluorescence assay (IFA) (133; 154;239), enzyme-linked immunosorbent assay 
(ELISA) using culture filtrate or affinity purified antigen (16;241), and dot 
immunoassay (197;259). Data on their clinical utility is sparse and none of these tests 
have replaced IHA. An immunochromatographic test kit has been developed for the 
rapid detection o f IgG and IgM antibodies to B. pseudomallei, and this has been 
evaluated in Thailand and Australia (40;54). Based on results for IgG, this kit 
represents an alternative to the IHA but the product will not be released onto the 
market.
1.2.8 Antimicrobial susceptibility of B. pseudomallei.
B. pseudomallei is intrinsically resistant to many antibiotics, including first, 
second and third-generation cephalosporins, aminoglycosides, penicillins and 
polymyxin (159;232). Inherent resistance to ampicillin and broad- and expanded- 
spectrum cephalosporins is due to the production o f beta-lactamases. This is a weakly 
inducible, membrane associated chromosomal cephalosporinase which is strongly 
active against carbenicillin, cefotaxime and cefuroxime, and inactivated by clavulanic 
acid (149). The beta-lactamase gene PenA has conserved motifs typical of class A beta- 
lactamase and is related to PenA (in B. cepacia) and Blal (in Yersinia enterocolitica) 
lineages (44). Macrolide and aminoglycoside resistance is mediated via AmrAB-OprA, 
a multidrug efflux pump which is specific for both macrolides and aminoglycoside
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antibiotics (161). Resistance to ceftazidime or amoxicillin with clavulanic acid (AMC) 
is rare, although the development of resistance to both drugs during treatment has been 
reported (75). Carbapenem resistance has not been reported in the published literature. 
Trimethoprim-sulfamethoxazole (TMP-SMX) susceptibility testing using the disc 
diffusion method grossly overestimates the rate of resistance (60 to 70%); the E test 
defines the rate o f resistance to be around 13% in Thailand (263), and at the much 
lower rate of 2% in Australia (174).
B. pseudomallei is usually susceptible to TMP-SMX, chloramphenicol, the 
tetracyclines, ceftazidime, carbapenems, AMC, piperacillin, piperacillin-tazobactam, 
ticarcillin-clavulanate, ampicillin-sulbactam, and carumonam (209). Carbapenem 
antibiotics have the greatest activity in vitro, while fluoroquinolones have poor activity 
in vitro (77;232), and had very low efficacy in a clinical trial (30). Rare clinical isolates 
are susceptible to gentamicin and macrolides, occurring in the order of approximately 1 
in every 1,000 isolates (202). The beta-lactams and ciprofloxacin are bactericidal in 
vitro, whereas the agents conventionally used to treat melioidosis during the oral phase 
of treatment (TMP-SMX plus doxycycline) have bacteriostatic activity only (77).
1.2.9 Treatment of melioidosis.
Empirical antimicrobial treatment of patients with suspected melioidosis is 
associated with a significant reduction in mortality rate (28). Cefotaxime and 
ceftriaxone are both less active than ceftazidime, and should not be used for empirical 
treatment of suspected melioidosis.
Treatment is divided into acute intravenous and oral eradicative phases. Initial 
intravenous therapy is required for at least 10 to 14 days, or until clinical response is 
seen (which ever is the longer). This duration may be exceeded in critically ill patients, 
those with extensive pulmonary disease, deep-seated collections or organ abscesses.
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Intravenous therapy for 4 to 6 weeks may be required for patients with osteomyelitis, 
septic arthritis or neurological melioidosis (147). After completing the initial parenteral 
phase, oral eradicative treatment is required for at least 12 to 20 weeks. Patients with 
mild localized disease are occasionally treated with oral antimicrobial drugs alone.
1.2.9.1 Initial parenteral treatment.
Ceftazidime is the treatment of choice for melioidosis. This is based on the most 
important clinical melioidosis trial showing a 50% reduction in mortality from 74% to 
37% associated with the use of ceftazidime compared with a combination of 
doxycycline, chloramphenicol and TM P-SMX (255). A reduction in mortality of a 
similar magnitude was reported for ceftazidime plus TMP-SMX compared with a 
combination of doxycycline, chloramphenicol and TMP-SMX (208). Ceftazidime, with 
or without TMP-SMX, became the standard of care for the initial therapy of patients in 
Thailand thereafter. Studies comparing cefoperazone-sulbactam plus TMP-SMX versus 
ceftazidime plus TMP-SMX showed equivalence for the two arms (43;231). 
Uncertainty over whether TMP-SMX is necessary during initial treatment has since 
been addressed by a randomised trial o f ceftazidime alone versus ceftazidime plus 
TM P-SMX (46). The addition of TM P-SMX to ceftazidime therapy during initial 
treatment o f severe melioidosis does not reduce the acute mortality rate (46).
The carbapenem antibiotics have several theoretical advantages over 
ceftazidime based on in vitro susceptibility data. However, a trial comparing imipenem 
and ceftazidime reported no difference in survival overall, or after 48 hours (201).
There was a higher but non-significant difference in treatment failure after 48 hours for 
the ceftazidime group (201). This trial was stopped prematurely due to interruption of 
imipenem supply, and as a result was underpowered. A retrospective review o f the use 
of meropenem in Australia concluded that it may be associated with improved
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outcomes in patients with severe sepsis associated with melioidosis, although this study 
was confounded by several concurrent changes in intensive care management (35). A 
prospective multicentre evaluation of meropenem versus ceftazidime is currently being 
performed in northeast Thailand.
AMC is the treatment of choice for pregnant women. A clinical study 
comparing AMC and ceftazidime demonstrated a similar mortality rate, but 4 of 75 
(5%) surviving patients in the ceftazidime group compared with 16 of 69 (23%) 
surviving patients in the AMC group were switched to an alternate regimen because of 
an unsatisfactory clinical response after >72 hours of treatment (224).
1.2.9.2 Route of parenteral ceftazidime: bolus versus infusion.
In a study o f the pharmacokinetic and pharmacodynamic effects of continuous 
infusion of ceftazidime vs intermittent bolus dosing, 34 patients suspected to have 
septicaemic melioidosis (of whom 20 had cultures positive for B. pseudomallei) were 
randomised to receive ceftazidime by either bolus injection or by constant infusion 
following a priming dose (6). Simulations based on these data and the ceftazidime 
sensitivity o f the B. pseudomallei isolates indicated that administration by constant 
infusion could provide adequate dosing with a significant dose reduction and cost 
saving (6). Ceftazidime infusions are now being used in Darwin, Australia to facilitate 
home intravenous therapy after discharge from hospital (118). The cost of peripherally 
inserted central catheter lines and infusions, together with the cost and infrastructure 
required to support home IV therapy prohibits their use in most endemic regions of 
Asia.
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1.2.9.3 Monitoring of antimicrobial levels during treatment.
In a retrospective evaluation of the relationship between serum bactericidal and 
inhibitory titers and treatment outcome in 195 adult Thai patients with severe 
melioidosis, pre- and 1 hour post-dose serum samples were collected after 48-72 hours 
of therapy, and serum inhibitory and bactericidal titrations were determined (200).
Drug regimens included ceftazidime (52% of patients), AMC (24%), imipenem (11%) 
or the conventional four-drug combination (11%). Overall mortality was 26% and 
outcome was not influenced by either inhibitory or bactericidal titers (200). Thus, these 
measures do not appear to have a role in the management of melioidosis. A time-kill 
study of 10 B. pseudomallei isolates using a range of concentrations demonstrated that 
a ceftazidime concentration of eight times the MIC yielded an optimal bactericidal 
effect (210), but the relevance o f this observation for clinical practice is not defined.
1.2.9.4 Adjuvant therapy.
Granulocyte colony-stimulating factor (G-CSF) was adopted for use in patients 
with septic shock due to melioidosis at the Royal Darwin Hospital, northern Australia 
in December 1998. This was associated with a decrease in mortality from 95% to 10%
(41). Risk factors, the duration o f illness before presentation and severity of illness 
were similar in patients before and after G-CSF introduction, but improvements in 
intensive care management also occurred during the study period. A randomised 
placebo-controlled trial o f G-CSF for severe melioidosis performed at 
Sappasithiprasong Hospital failed to show a difference in mortality (38). A placebo- 
controlled trial of an intravenous PAF receptor antagonist (lexipafant) in 131 adult Thai 
patients with suspected severe sepsis included 36 patients with melioidosis; no benefit 
was detected (223). Other interventions shown to be of benefit in critically ill septic 
patients such as goal-directed therapy (192), low tidal volume ventilation (3), intensive
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glycaemic control (243), and activated protein C (19) have not been evaluated in 
patients with melioidosis.
1.2.9.5 Supportive treatment and other management of patients with melioidosis.
Initial intensive care management of severe melioidosis is similar to that of any 
severe sepsis. Patients need to be resuscitated with correction of electrolyte imbalance 
and adequate intravenous fluid, since hypovolemia is common in the acute phase. 
Septic arthritis requires joint washout, and large accessible abscesses require drainage. 
For suppurative parotitis, surgical drainage is required to avoid lower motor neuron 
seventh-nerve palsy. Standard of care and availability of ICU in different geographical 
regions is likely to be an important contributor to the marked difference in outcome 
between Australia and Thailand.
Routine laboratory tests should be performed to detect the onset of acute renal 
failure, abnormal liver function tests and anaemia, all o f which are well recognized 
during severe melioidosis. Arterial blood gases should be taken in patients with severe 
sepsis, lung involvement and/or any evidence of respiratory impairment. Serum C- 
reactive protein levels (CRP) do not appear to aid patient management, based on a 
review of CRP in 175 patients which found that admission CRP may be normal or only 
mildly elevated, including patients with severe sepsis, fatal cases, and in recurrent 
melioidosis (39).
Chest radiographs should be taken in all patients with suspected melioidosis. 
Common radiographic patterns include diffuse interstitial shadowing considered 
consistent with blood borne spread o f infection, localized patchy alveolar infiltrate, 
focal, multifocal or lobar consolidation, pleural effusion and upper-lobe involvement 
which may include cavitation (188). Patients may develop empyema and/or lung 
abscess. Abdominal ultrasound or CT scan is required to detect liver and/or splenic
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abscesses. Clinical evidence o f prostatic involvement requires appropriate imaging 
(trans-rectal ultrasound or CT scan) (225).
1.2.9.6 Oral eradicative treatment.
Oral therapy after completion o f parenteral treatment is required to eradicate the 
organism and prevent relapse o f the disease. TMP-SMX based regimens are the 
treatment o f choice. TM P-SM X is used in Australia while TMP-SMX plus doxycycline 
is generally used in Thailand. The three drug regimen used in Thailand replaces a 
previous four drug regimen that included chloramphenicol, which was discontinued 
following a prospective randomised controlled trial that showed no difference in the 
rate of recurrence between the three-drug and four-drug regimens (26). Doxycycline 
monotherapy is not appropriate since this was shown to be associated with a 
significantly higher culture-confirmed relapse and clinical treatment failure compared 
with the four-drug regimen (27).
AMC is the oral treatment of choice for pregnant women, young children, and 
for those with hypersensitivity reactions to TMP-SMX or doxycycline. In a trial of 
AMC versus the four-drug combination, the rate of relapse was higher for the AMC 
group (16% versus 4%) but only half of the patients completed the intended 20 weeks 
of therapy. Poor compliance proved the most significant risk factor for subsequent 
relapse (184). Uncertainty remains as to whether 20 weeks of AMC is less effective 
than combination treatment. AMC does not pass through the blood brain barrier and 
should not be used in patients with neurological melioidosis (147).
Fluoroquinolones are not recommended for the oral treatment of melioidosis. A 
comparison of ciprofloxacin and azithromycin for 12 weeks versus TMP-SMX and 
doxycycline for 20 weeks demonstrated a relapse rate of 22% and 3%, respectively
(42). The relative contribution o f differences in treatment duration in the two arms to
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the rate of relapse is not known. However, ciprofloxacin or ofloxacin given for a 
median of 15 weeks to treat 57 adult patients with melioidosis was associated with an 
unacceptably high failure rate of 29% (30).
Options for treatment of patients with neurological melioidosis and intolerance 
to TM P-SMX or infected with a strain that is resistant to TMP-SMX are very limited. 
Prolonged parenteral therapy is impossible in resource-poor regions, where probably 
the best option is chloramphenicol plus doxycycline (147). New agents for the oral 
eradicative treatment of melioidosis are much needed. B pseudomallei is susceptible to 
some of new oral cephalosporins including cefixime and cefetamet (77). These drugs 
should be further evaluated for safety and efficacy in the oral treatment of melioidosis.
1.2.9.7 Summary of recommendations for antimicrobial therapy of melioidosis.
Initial parenteral therapy is given for at least 10 to 14 days, until there is clear 
evidence o f clinical improvement. Ceftazidime or a carbapenem drug is the treatment 
of choice (table 1-3). Ceftazidime is the drug of choice in Thailand, with a switch to a 
carbapenem antibiotic if the patient fails treatment. Parenteral treatment at the Royal 
Darwin Hospital is ceftazidime, or meropenem plus G-CSF if the patient has septic 
shock (41). The addition of TMP-SMX to ceftazidime or meropenem during the initial 
intensive therapy phase has been phased out in Darwin (62), although this drug is still 
used to treat patients with neurological (147) or prostatic melioidosis (171). Alternative 
parenteral treatment for pregnant women in Thailand is AMC. Treatment duration 
longer than 14 days may be required in critically ill patients, those with extensive 
pulmonary disease, deep-seated collections or organ abscesses. Patients with large 
abscesses or empyema often have fluctuating fevers for more than 1 month. Four to six 
weeks of parenteral treatment may be required for patients with osteomyelitis, septic 
arthritis or neurological melioidosis (147). Enlargement of an existing abscess, the
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appearance of new abscesses or seeding to a joint are common during the first week of 
parenteral treatment and should not necessarily be assumed to be a sign o f treatment 
failure.
Oral eradicative treatment for at least 12-20 weeks consists of TMP-SMX alone 
(Australia) or together with doxycycline (adults in Thailand) (table 1-3). Close follow- 
up and monitoring of drug adherence are important. Currie et al. reported that the 
recurrence rate associated with TMP-SMX relates almost exclusively to non-compliant 
patients (64). First-line oral treatment for pregnant women and children is AMC; this is 
also an alternative for adults who cannot tolerate TMP-SMX. AMC does not pass 
through blood brain barrier and should not be used in patients with neurological 
melioidosis (147).
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Table 1-3. Antimicrobial treatment of melioidosis.
Sappasithiprasong Hospital Royal Darwin Hospital
a. In itia l parenteral therapy
Ceftazidime 40 mg/kg (up to 2 g) every 8 
hours, or meropenem 25 mg/kg (up to 1 g) 
every 8 hours, or imipenem 20 mg/kg (up 
to 1 g) every 8 hours, or AMC at 20/5 
mg/kg (up to 1.2 g) every 4 hours for 
pregnant woman.
Duration at least 10 to 14 days or until 
clear clinical improvement, which ever is 
the longer.
Ceftazidime 50 mg/kg (up to 2 g) every 
6 hours, or meropenem 25 mg/kg (up to 
1 g) every 8 hours plus G-CSF 
(filigrastin) 300 pg for 10 days if patient 
has septic shock.
Duration of therapy at least 14 days, and 
longer (4 to 8 weeks) for deep-seated 
infection.
b. Oral eradicative therapy
Adults: TMP-SMX 5/25 mg/kg (up to 
320/1,600 mg) respectively every 12 hours, 
a plus doxycycline 2 mg/kg (up to lOOmg) 
every 12 hours.
Children <8 years and pregnant women:
AMC 20/5 mg/kg (up to 1500/375 mg) 
respectively every 8 hours. b
Duration at least 12-20 weeks.
TMP-SMX 8/40 mg/kg (up to 320/1,600 
mg) every 12 hours.
Duration at least 3-6 months.
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a Equivalent to 3 x 480mg TMP-SMX tablets every 12 hours for a patient <60kg, and 4 
x 480mg TM P-SM X tablets every 12 hours for a patient >60kg 
b Equivalent to 2 x 625mg AMC tablets every 8 hours for an adult patient <60kg, and 3 
x 625 mg AMC tablets every 8 hours for an adult patient >60kg
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1.3 Recurrent melioidosis.
The single most important complication for patients who survive their first 
episode of melioidosis is recurrence, which may occur despite prolonged oral 
eradicative antimicrobial treatment. Recurrent melioidosis is defined as the 
development of new symptoms and signs of infection after responding to therapy for 
the primary episode. M ortality from recurrence has been reported to be as high as that 
for primary infection (29). To date, recurrence has been considered to be largely 
synonymous with relapse caused by the re-emergence of a quiescent focus, rather than 
re-infection with a new strain.
1.3.1 Background of recurrent melioidosis.
In 1975, Mays and Ricketts described a patient with melioidosis who developed 
a sputum culture positive for B. pseudomallei, 3 weeks after completing three and a half 
months treatment with oral tetracycline followed by a further month of 
chloramphenicol (157). A case series in North Queensland Australia between 1979 and 
1981 described recurrent melioidosis in 3 of 14 (21%) patients, all three of whom drank 
alcohol to excess and were poorly compliant with the oral antimicrobial medication 
(104).
There were no guidelines for oral eradicative treatment at that time. In 1967, 
using experience from the Vietnam war Dr Deller recommended treatment with a three 
drug combination of 12 grams of chloramphenicol, 3 grams of kanamycin and 6 grams 
of novobiocin for the treatment of acute melioidosis, or 1 gram of tetracycline daily for 
chronic melioidosis (1). The necessity of oral eradicative treatment after recovery from 
acute melioidosis was not defined. Failure of tetracycline monotherapy in chronic 
melioidosis was also reported in 1971 (228). Susceptibility testing showed that the 
strain had developed resistance to tetracycline after three weeks of treatment.
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Chloramphenicol was found to be effective but was associated with adverse drug events 
(178). B. pseudomallei was also found to be susceptible to TMP-SMX and successful 
treatment with this drug combination was reported (93; 126).
Various drug combinations were subsequently recommended for oral 
eradicative treatment with the aim of reducing the rate of recurrence. In 1981, Rode and 
W ebling suggested a four-drug combination of tetracycline or doxycycline, 
chloramphenicol, and TMP-SMX (193), and Puthucheary et al. recommended a 
combination of tetracycline and chloramphenicol for at least 6 months to prevent 
relapse (182). Chloramphenicol in the four-drug regimen was normally prescribed only 
for the first month (157). The four-drug regimen was widely adopted in Thailand where 
it continued to be used until the publication in 2005 of a trial indicating that three drug 
combination of doxycycline and TMP-SMX was as effective as the four drug 
combination (26). The recommended duration of oral treatment varied from 3 to 6 
months (104).
A prospective study of 118 melioidosis patients in Thailand from 1986 to 1991 
found that 27 (23%) had culture-proven recurrent melioidosis (29). The median time 
from start o f oral eradicative treatment to recurrence was 21 weeks (range 1 - 290 
weeks). Bacteraem ia recurred in 44% of patients, and 27% of the patients died. Poor 
compliance was found during interview with three patients with recurrence. Recurrent 
strains were found to be less susceptible to the antibiotics used in three cases. The 
recurrence rate was also found to be very high (19%) in a retrospective review from 
Pahang, M alaysia (115).
In a 10-year prospective study of melioidosis in the Northern Territory of 
Australia between 1989 and 1999, 27 of 222 (13%) patients surviving the acute phase 
developed recurrence (64). The mean time to recurrence was 32 weeks. H alf of the
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recurrent patients had adhered poorly with oral antibiotic therapy, and 10 represented 
failure of eradication with doxycycline monotherapy.
1.3.2 Clinical trials of oral eradicative treatment to prevent recurrence.
A four-drug combination of chloramphenicol, doxycycline and TMP-SMX was 
the recommended oral eradicative treatment for melioidosis in Thailand from 1981 
(193); however, adverse drug reactions from these four drugs are extremely high. The 
use of high dose chloramphenicol for long periods is associated with haematopoietic 
suppression and the induction o f aplastic anaemia. Allergic reactions to sulphonamides 
are potentially severe and the tetracyclines cannot be used in pregnancy, childhood and 
renal failure. A large number o f tablets must be taken each day, which reduces the 
chances of good compliance. This led to the evaluation of alternatives, as summarized 
in table 1-4.
A pilot study of AMC monotherapy was conducted between June 1986 and 
August 1989 at Sappasithiprasong Hospital, northeast Thailand (221). Intended 
duration of therapy was a minimum of 8 weeks. AMC was given to 46 patients for a 
median duration of 7.5 weeks. Culture-proven recurrent melioidosis occurred in 13 of 
46 (28%) cases after a median follow-up of 6 months. The drug was generally tolerated 
despite the high doses used and thereafter was considered an alternative for children, 
pregnant women, infection with a B. pseudomallei strain resistant to TMP-SMX, and 
for patients who were allergic to any drug within the four-drug regimen.
An open randomised controlled trial comparing AMC with the four-drug 
regimen was conducted between June 1989 and October 1992 (184). A total of 101 
patients who recovered from acute melioidosis were enrolled into the study. Because of 
the high recurrence rate in the AMC study described above (221), total duration of 
treatment was extended to 20 weeks. Recurrent melioidosis occurred in 2 of 52 (4%)
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patients in the oral four-drug regimen group and 8 of 49 (16%) patients in the oral 
AMC group (adjusted RR 0.4; 95% confidence interval (Cl), 0.2-1.2) after a median 
follow-up o f 18 months. The study suggested that AMC is safer and better tolerated, 
but may be less effective than the oral four-drug regimen. The minimum duration of 
oral treatment was defined thereafter as 12 to 20 weeks.
Although the fluoroquinolones have intermediate activity against B. 
pseudomallei in vitro in terms of minimum inhibitory concentration, efficacy in 
melioidosis is poor. Oral ciprofloxacin or ofloxacin monotherapy was evaluated in a 
study conducted between June 1991 and March 1995 at Sappasithiprasong Hospital 
(30). A total of 57 patients were enrolled into the study and 13 treatment failures (29%) 
occurred; o f these, 5 failures represented treatment failure of the primary episode, and 8 
had recurrence after an initial response. In one patient, fluoroquinolone resistance 
developed within one week of starting treatment. Effectiveness of a fluoroquinolone- 
based regimen was evaluated again in an open RCT conducted between August 1997 
and July 1998 (42). A combination o f ciprofloxacin and azithromycin was compared 
with TMP-SMX plus doxycycline. O f 65 patients enrolled, 7 of 32 (22%) patients in 
the ciprofloxacin arm and 1 o f 33 (3%) patients in three-drug arm had recurrent 
melioidosis. As a result of these two studies, fluoroquinolones are now reserved as 
third-line drugs for patients who are either intolerant to other available antibiotics or 
who are infected with multi-resistant organisms.
The four-drug regimen has a high risk of toxicity and there is in vitro evidence 
of antagonism between the component drugs (76). TMP-SMX has been reported to 
antagonize the effect of chloramphenicol and doxycycline in vitro. Based on evidence 
of successful treatment with doxycycline monotherapy in Australia during an outbreak 
between 1990 and 1991 (63), an open randomised controlled trial comparing 
doxycycline alone with the four-drug regimen was conducted between October 1994
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and August 1997 (27). O f 87 patients enrolled, 1 o f 44 (2%) patients randomised to the 
four-drug regimen and 11 of 43 (26%) patients randomised to doxycycline 
monotherapy had recurrent infection (HR 12.0; 95%CI, 1.4-100.8). Development of 
doxycycline resistance was found in one patient with recurrence who was treated with 
doxycycline monotherapy. This study showed that doxycycline monotherapy cannot be 
recommended.
Chloramphenicol can cause serious toxicity and is associated with a high rate of 
adverse events, including gastrointestinal intolerance and allergic reaction, so the idea 
of removing this from the treatment protocol was a popular one (42;66). An open 
randomised controlled trial comparing four-drugs with three-drugs (minus 
chloramphenicol) was conducted between July 1998 and October 2002 (26). There was 
no difference in the.recurrence rate, but the three-drug regimen was associated with a 
much lower rate o f side effects (19% vs 36%). The duration of oral therapy was 
significantly associated with recurrent infection. Patients receiving treatment for less 
than 12 weeks had a 5.7 fold increase of recurrence or death. The three-drug regimen is 
now the standard treatment for oral eradicative treatment of melioidosis in Thailand.
As doxycycline monotherapy is ineffective as an oral eradicative treatment (27) 
and TMP-SMX monotherapy has been used successfully in Australia (64), the role of 
doxycycline in the three-drug regimen has been questioned. A double-blind randomised 
controlled trial comparing the three-drug regimen with TM P-SMX monotherapy is now 
being conducted in Thailand (ISRCTN86140460). This study aims to enroll 635 
patients who will complete a minimum of 1 year follow-up.
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1.3.3 Risk factors for recurrent melioidosis.
Identified risk factors for recurrent melioidosis are summarized in table 1-5. An 
important limitation in the interpretation of these findings is that recurrence has been 
largely considered to represent relapse, and risk factors have not been considered 
separately for relapse versus re-infection. For example, it is unlikely that oral 
eradicative treatment is associated with re-infection if this occurred after the 
completion of antibiotic therapy.
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Table 1-5. Published risk factors for recurrent melioidosis.
Clinical severity M ultifocal infection plus bacteraemia was associated with a 
4.7 (95%CI, 1.6-14.1) times higher risk of recurrence 
compared with localized infection (29).
Infection involving more than one non-contiguous organ 
with or without bacteraemia was associated with 1.8 higher 
risk of recurrence (95%CI, 1.0-3.4) (184).
Parenteral treatment Initial parenteral treatment with ceftazidime had a 2-fold 
lower risk of recurrence (95%CI, 1.1-3.4) compared to 
treatment with other parenteral drugs (AMC or four-drug 
regimen) (29). However, this was not reproduced in later 
RCT studies (184).
Oral treatment Poor drug compliance was found in 15 of 32 (47%) patients 
with recurrent melioidosis in Australia (64). A higher risk 
of recurrent melioidosis was reported in patients who did 
not take their drugs regularly (RR 4.9%; 95%CI, 1.2-20.3) 
(184).
Oral treatment -  duration In one study, treatment for more than 8 weeks was 
negatively associated with recurrent melioidosis (RR 0.4; 
95%CI, 0.2-0.9) (29). In a second study, treatment for less 
than 12 weeks was associated with recurrent melioidosis 
(HR 5.7; 95%CI, 2.6-12.5) (26). The relationship between 
shorter duration of treatment and recurrent melioidosis was 
also supported by a review of patients in Thailand who 
were treated for 8 weeks versus 12-20 weeks, the rate of
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recurrence decreasing significantly from 23% to 10% (59% 
reduction; 95%CI, 50-69%) (184).
Oral treatment regimen -  
AMC
Patients who received oral AMC compared to the four-drug 
regimen had 3.3 (95%CI, 1.4-9.0) times higher risk of 
recurrence (29). The inferior effectiveness of AMC was 
also shown in a later prospective RCT, in which the relative 
risk of recurrent melioidosis for the four-drug regimen was 
0.4 (95%CI, 0.2-1.2) compared to that of AMC (184).
Oral treatment regimen -
doxycycline
monotherapy
Doxycycline monotherapy was associated with a higher rate 
o f recurrent melioidosis compared to four-drug regimen 
(HR 12.0; 95%CI, 1.4-100.8) (27).
Oral treatment regimen -
fluoroquinolone-based
regimens
Ciprofloxacin or ofloxacin monotherapy was associated 
with a higher rate of recurrent melioidosis (30).
In an RCT, patients treated with ciprofloxacin plus 
azithromycin had a higher recurrence rate compared to 
patients treated with three-drug regimen (22% vs 3%) (42).
Clinical manifestations No association found with recurrence (29).
Underlying disease No association found with recurrence (29; 184).
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1.3.4 Clinical manifestations of recurrent melioidosis.
Clinical manifestations of recurrent melioidosis are protean. Recurrent 
melioidosis may affect the same organs or different sites to those affected during the 
primary infection. Recurrent melioidosis was reported to affect the same organ as in the 
primary presentation in less than half (44%) of cases in Thailand (29). O f 27 patients 
with recurrence, 7 patients developed recurrence while still receiving oral eradicative 
treatment. Seasonal variation of the onset of recurrence has not been reported.
Recurrent melioidosis can present as soon as 1 month after the start o f oral eradicative 
treatment (64). This may reflect clinical fluctuations in the course of recovery from the 
primary episode after switching from parenteral treatment to oral eradicative treatment.
A patient reported by Mays and Ricketts initially presented with pneumonia in 
the right upper lobe and B. pseudomallei was isolated from cultures of sputum and 
bronchial lavage (157). He had recurrent melioidosis three weeks after antibiotics were 
discontinued with cultures positive from sputum. Puthucheary et al. also reported a 
patient with the reappearance of a positive blood culture during oral eradicative 
treatment with tetracycline (183). A further example is a case who had multifocal 
abscesses affecting the prostate, left elbow and right knees, who later had recurrent 
disease associated with a deep neck abscess and recurrent tibial osteomyelitis (131).
AMC does not reach high concentrations in the CSF, and a case report of 
recurrent melioidosis after AMC treatment following probable primary central nervous 
system infection has been reported (147). The primary presentation was B. 
pseudomallei bacteraemia and two generalized tonic-clonic convulsions. Her CT was 
reported to be normal. She was treated with a combination of TM P-SMX and 
doxycycline for 1 month during which she complained of nausea and vomiting. As a 
result, oral antimicrobials were switched to AMC. Two months later, she represented 
with a progressive left hemiparesis. A CT scan showed an epidural abscess, pus from
54
which grew B. pseudomallei. It is likely that there was a small infective lesion in the 
central nervous system during her primary infection which was not detected by the first 
CT scan.
1.3.5 Diagnosis of recurrent melioidosis.
Definite diagnosis of recurrence is based on the isolation of B. pseudomallei 
from a clinical specimen taken from a patient with a history of melioidosis. Cultures 
may be negative, however, from patients for whom there is a strong probability of 
recurrence. Furthermore, some patients may have a period of prolonged culture 
positivity during the primary infection which does not represent recurrence (64). Thus, 
careful clinical judgm ent is required in defining when and if recurrence has occurred.
1.3.6 Antimicrobial susceptibility of B. pseudomallei associated with recurrent 
melioidosis.
A cohort study conducted in northern Australia found that three of nine isolates 
(33%) associated with relapse cultured from patients treated with doxycycline 
monotherapy had acquired resistance to doxycycline (64). In the same study, one 
patient who relapsed after treatment with oral TM P-SMX had an organism that had 
acquired resistance to TMP-SMX. The development of resistance was found in 3 of 25 
(12%) patients with recurrent melioidosis in Thailand (29). Development of drug 
resistance was associated with resistance in a patient who developed features of 
recurrence 10 days after completing a 10 week course o f AMC treatment (221). 
Karcher et al. reported a patient with a second recurrent episode in which the isolate 
had become resistance to AMC after treatment with oral AMC for 5 months for the 
primary infection and a further 2 months for the first recurrence (131).
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1.3.7 Antimicrobial treatment of recurrent melioidosis.
1.3.7.1 Parenteral antimicrobial treatment in acute phase.
Parenteral antibiotics used for primary melioidosis are effective drugs for the 
treatment o f recurrence unless resistance has emerged to the drug used. Emergence of 
resistance to ceftazidime in patients with recurrence has not been reported, and this 
remains the treatment of choice (27;29;64). Specific guidelines for the duration of 
parenteral treatment for recurrent melioidosis have not been reported (27;29;64), and 
the standard guidelines o f at least 10 to 14 days apply.
1.3.7.2 Oral antimicrobial treatment in eradicative phase.
Successful treatment o f recurrence has been reported for TMP-SMX with or 
without doxycycline or AMC (27;29;64). In practice, AMC may be used to treat 
recurrence if  the primary episode was treated with TMP-SMX (personal 
communication, Chaowagul, W .). However, the effectiveness of AMC as an oral 
eradicative treatment regimen is lower than a TMP-SMX based regimen, and the latter 
should remain the treatment o f choice for recurrence due to relapse and re-infection.
Duration of oral treatment required for recurrent melioidosis is uncertain 
(27;29;64). Durations of longer than 20 weeks may be required (27), but as for primary 
infection this should be guided by clinical response.
1.3.8 Relapse or re-infection as a cause of recurrent melioidosis.
Previous studies have largely treated recurrence as a homogenous condition, 
with cases being assumed to have resulted from relapse of a persistent focus of 
infection. However, recurrence can be caused by relapse following failure to eradicate 
bacteria responsible for the primary infection, or by re-infection after an exposure to a 
new bacterial strain. Distinguishing between the two is important since clinical trials of
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oral therapy for melioidosis commonly use recurrent disease as a marker for treatment 
failure. Several small typing studies involving 5 to 25 patients with recurrence that 
compared bacterial isolates from the first and second episode of infection have 
suggested that recurrent melioidosis is not always due to relapse.
The first study performed to distinguish between the relapse and re-infection 
was reported from Thailand in 1993 (80). This study included 25 patients with recurrent 
melioidosis presenting between 1986 and 1991 (29). BamH l restriction digest 
ribotyping was used to compare strains from the first and second presentation (80). 
Primary and recurrent isolates were identical or highly similar for 23 patients, while 2 
recurrent episodes (8%) were caused by isolates that were genetically different from the 
isolate causing primary infection, indicating that relapse was the dominant cause of 
recurrence rather than re-infection.
A study in northern Australia published in 1995 compared B. pseudomallei 
isolated from 10 patients with primary and recurrent melioidosis using RAPD (105). 
These strains were later re-examined using PFGE (64). The mean time period between 
primary episode and recurrence was 8 months. Two of 32 recurrent episodes (6%) were 
classified as re-infection; the interval between primary infection and recurrence was 1.2 
and 4.8 years, respectively (64; 105). One patient with chronic osteomyelitis was 
thought to have had relapse with 1 of 2 strains originally infecting the patient (64).
A study from Malaysia of 5 patients with recurrence examined strains using 
BamHl ribotyping and pulsed-field gel electrophoresis (PFGE) of X bal digests (240). 
One of five patients (20%) with recurrent episodes was infected with a strain that was 
clearly distinct from the original primary isolate. These studies are consistent with the 
idea that not all patients with recurrent disease have relapse. However, they involved 
small numbers of patients, and the typing methods used are not unambiguous in that 
PFGE banding patterns could potentially change in the host over time.
57
1.3.9 Polyclonal infection could cause misclassification of recurrence.
An important possible source of error when determining the cause of recurrence 
could arise if simultaneous infection with more than one strain of B. pseudomallei was 
common and different strains from the primary and recurrent episode were picked by 
chance for genotyping; this would lead to misclassification of relapse as re-infection. In 
a study of recurrent melioidosis, a sweep of colonies was taken from the isolation plates 
in an attempt to avoid this, but only single colonies were subsequently used for typing; 
therefore, selection of a single strain is likely to have occurred (80).
Infection with multiple strains of B. pseudomallei was first demonstrated by 
Sexton et al. (198). In this study, 74 clinical isolates of B. pseudomallei from 34 
patients were examined. Ten ribotypes were identified from a combination of 
restriction fragment polymorphisms from ZscoRI, Sail, H indlll, and Pstl chromosomal 
digests. Isolates with two different ribotype patterns were found in one patient (3%), 
one each in sputum and urine. This prospective study demonstrated that infection with 
more than one strain can occur. A second study reported that a patient with two 
recurrent episodes was initially infected with two strains (80). A recent retrospective 
study suggested that polyclonal infection may be relatively common. An evaluation of 
samples from 18 patients presenting to Sappasithiprasong Hospital, northeast Thailand 
between 1992 and 1993 was conducted (176). Between 10 and 40 colonies were 
selected from primary culture plates which were compared using a combination of 
Bam H l ribotype pattern and PFGE pattern of X bal DNA digests. Five of 18 patients 
(28%; 95%CI, 10%-53%) were shown to be infected with more than one genotypic 
strain. Furthermore, patients with polyclonal infection had more severe disease and a 
poorer outcome. This study suggested that the incidence of polyclonal infection may be 
higher than previously thought. However, this study was small and conducted in a 
selected population, which could introduce bias.
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1.3.10 B. pseudomallei genotypes in the environment could influence the
classification of recurrence.
Re-infection could be misclassified as relapse in the event that the population 
genetic structure of B. pseudomallei in the environment was highly clonal. In this case, 
an individual could have independent infections caused by the same bacterial clone. An 
understanding of the bacterial population genetic structure in the environment is 
required in order to assess this possibility.
In 1995, Hasse et a l  used RAPD to determine the genotypes of B. pseudomallei 
strains associated with an outbreak of melioidosis in goats on a farm near Darwin, 
Australia and from serial soil samples from the paddock between 1992 and 1993 (106). 
Fourteen o f the 15 goats were infected with the same strain. Only 3 of 24 soil isolates 
were genetically identical to this outbreak strain. One goat was infected by a different 
strain, and this was identified from 9 of the soil samples. The remaining 12 soil isolates 
gave two further RAPD patterns that were not identified from goat strains. This study 
confirmed that soil isolates can be identical to epidemiologically related clinical 
isolates, and showed that there was a degree of genetic diversity of B. pseudomallei 
over a restricted area.
In 1997, Vadivelu et al. used Bam H I ribotyping and PFGE of Xbal digests to 
examine 49 isolates of B. pseudomallei from 49 sporadic melioidosis cases in Malaysia 
over an 18-year period (242). Five ribotype patterns were identified; in addition, PFGE 
revealed different strains within the same ribotype. Two pairs of isolates from unrelated 
cases gave an indistinguishable PFGE pattern. The first pair was from two patients 
separated by 7 years, and the second pair was from patients living in different towns. 
This study suggested that independent infections can occur with an indistinguishable 
strain.
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In 2004, Cheng et a l  used a combination o f PFGE and MLST to examine 87 B. 
pseudomallei isolates from clinical cases and the environment (36). A total of 48 STs 
were defined, suggesting genetic diversity of the population. Using MLST, 
Vesaratchavest et a l  examined 183 clinical and 83 soil isolates (245). A total of 123 
STs were defined. These studies suggest that B. pseudomallei in the environment and 
associated with disease is genetically diverse. One issue that is not addressed by these 
two studies is whether specific STs predominate over a small area of land, such as that 
farmed by a single farmer. If this were so, then repeated exposure could lead to re­
infection with a dominant clone.
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1.4 Aims of this dissertation.
1.4.1 To undertake a large study in northeast Thailand to determine the proportion of 
recurrent melioidosis that is due to relapse versus re-infection as defined by 
bacterial genotyping of primary and recurrent strains using a combination of 
PFGE and MLST. This will include the following nested studies:
i. Relapse could be misclassified as re-infection in the event that 
polyclonal infection during the primary episode was common, and 
different strains were picked from the primary and recurrent cultures for 
genotyping. The rate o f primary infection with more than one strain will 
be addressed during a large prospective study in northeast Thailand in 
which genotyping will be applied to multiple colonies from multiple 
sites from a given patient.
ii. Re-infection could be misclassified as relapse in the event that the 
population genetic structure o f B. pseudomallei in the environment was 
highly clonal. This will be studied by defining the genotypes of B. 
pseudomallei isolated from soil sampled from a small defined area of 
land in northeast Thailand, together with an analysis of MLST data held 
in the public database.
1.4.2 In the event that recurrence is not simply due to relapse, a database of nearly
1,000 patients with melioidosis presenting to Sappasithiprasong Hospital will be 
used to:
6 1
define the specific risk factors for relapse and for re-infection
compare and contrast the clinical features of relapse and re-infection
develop a clinical scoring system that can be used to predict whether 
recurrent melioidosis is due to relapse or re-infection
Chapter 2. Materials and Methods.
2.1 Chemical and reagents.
All chemicals and reagents were obtained from Sigma-Aldrich Company Ltd. or 
M erck Ltd. Bacterial culture media were obtained from Oxoid. Sterile plastic ware was 
obtained from Falcon, Becton Dickinson Ltd. and Terumo. The ingredients and 
amounts used to prepare reagents were described in appendix.
2.2 Bacterial culture and storage conditions.
2.2.1 Liquid medium.
B. pseudomallei was grown in TSB under static conditions at 37°C in air. 
Cultures were routinely grown in 3 ml of media contained in 15 ml universal 
containers.
2.2.2 Solid media.
All agar plates used in this study were prepared as recommended by the 
manufacturer. B. pseudomallei was routinely cultured on Ashdown’s Selective Agar at 
37°C in air. Other media used during clinical studies are specified in the relevant 
results chapters.
2.2.3 Bacterial storage.
B. pseudomallei was suspended in TSB containing glycerol (15%, v/v) and 
stored in locked freezers at -80°C.
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2.3 Laboratory facilities.
All experimental work involving viable bacterial cells was performed in a 
Category 3 containment facility under negative pressure of -5 0  Pascals. All work that 
may create aerosols or splatter was carried out inside a class II biological safety 
cabinet.
2.4 B. pseudomallei identification.
All isolates were identified in the clinical diagnostic laboratory in Ubon 
Ratchathani as B. pseudomallei based on growth on Ashdown’s agar with typical 
colony morphology after 3 or 4 days of incubation at 37°C in air, a positive oxidase 
test, and resistance to Gentamicin (disc strength 10|Lig) and Colistin (disc strength 
10|ig) after overnight incubation at 37°C in air on Columbia agar (250). Further 
confirmation was obtained using a highly specific latex agglutination reaction (262). In 
brief, a small amount of colony is emulsified using a sterile toothpick into a solution 
containing latex particles coated with a monoclonal antibody specific for a 200-kD 
surface antigen of B. pseudomallei. The reaction is read within 1-2 min. The presence 
of agglutination is taken as a positive reaction. E. coli is used as a negative control. API 
20NE biochemical strips were used as recommended by the manufacturer (Bio- 
Merieux. Inc.), if any uncertainly remained about the bacterial species. Typical API 
profiles are 1156577 or 1156576 by APILAB Plus software; this gives an automated 
interpretation on a computer workstation (bioMerieux, 2005). To exclude the 
possibility that some isolates were B. thailandensis, all isolates were tested for their 
inability to assimilate arabinose. This was performed in batches at the end of the year 
in the W ellcome Unit, Bangkok. B. pseudomallei is negative and B. thailandensis is 
positive (262). Isolates were point inoculated onto agar plates containing arabinose as
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the only source o f nutrition. B. pseudomallei fails to grow on this medium after 48 
hours incubation at 37°C in air, while B. thailandensis shows growth.
2.5 PFGE.
2.5.1 Introduction.
PFGE enables DNA megabase-sized fragments to be separated according to 
size, allowing chromosomal RFLPs (generated by rare cutting enzymes) to be 
examined. PFGE has been used both for epidemiological studies and to examine the 
physical map of bacterial chromosomes. A specialized electrophoresis chamber is used 
(the Contour-clamped Homogenous Electrophoresis Field (CHEF) DRIII was used in 
the current study), in which an agarose gel is positioned between 3 sets of electrodes 
forming a hexagonal shape around the gel. Current is applied to one set of electrodes 
creating an electric field across the tank. The current is then switched to a second set of 
electrodes, changing the direction of the field. After a defined period of time it 
switches to the third set of electrodes, shifting the field again. This pulsed electric field 
causes the DNA to periodically re-orientate its direction of migration as it moves up the 
gel (60;230). The rate o f migration through the gel is determined by the size of each 
DNA fragment, as smaller DNA fragments are able to re-orientate faster than large 
ones (99).
Many diverse organisms have been examined using a variety of different 
restriction enzymes. The choice of restriction enzyme will depend on the average 
number of specific restriction sites in a particular bacterial genome, and the required 
average number o f the resulting fragments. SpeI is the enzyme usually used to cut B. 
pseudomallei. This cuts between 5’-A/CTAGT-3’ sites, and cuts the B. pseudomallei 
genome into approximately 20 bands ranging in size from 20 to 800 kb (34).
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2.5.2 Procedure of PFGE.
2.5.2.1 Preparation of DNA.
To prepare chromosomal DNA, bacterial cells were streaked onto an Ashdown's 
agar plate and incubated at 37°C overnight. Bacterial colonies were then harvested and 
suspended in a tube containing 2 ml of SE buffer (75 mM NaCl and 25 mM EDTA, pH 
7.5). The solution was mixed to obtain a homogenous solution and the concentration of 
B. pseudomallei was adjusted to an optical density at 600 nm of 1.2. The solution was 
then mixed with an equal volume of molten 2% low melting agarose (Invitrogen) and 
pipetted into PFGE plug moulds (Bio-Rad Laboratories, Richmond, CA). Agarose 
blocks were maintained at 56°C for 24 hours in lysis buffer (0.1% SDS and 25 mM 
EDTA, pH 8.0) containing 500 pg/ml proteinase K (Invitrogen). The cell debris and 
proteinase K were then removed by washing three times with TE buffer (10 mM Tris 
and 10 mM EDTA). DNA plugs were then equilibrated in TE buffer for 1 hour at room 
temperature.
2.5.2.2 Restriction endonuclease digestion and PFGE.
Before restriction enzyme digestion, agarose plugs were divided into 2 mm 
thick blocks and equilibrated for 30 minutes in 100 pi of lx  restriction enzyme buffer. 
The buffer was aspirated and samples were then digested with a restriction enzyme in 
100 pi of final solution containing 10 units o f SpeI enzyme (5’-ACTAGT-3’; New 
England Biolabs, Beverly, MA). The blocks were incubated at 37°C overnight.
PFGE was performed using the CHEF-DRIII system (Bio-Rad Laboratories, 
Richmond, CA) in gels o f 1% gel agarose in 0.5x TBE buffer (45 mM Tris, 45 mM 
boric acid and 1 mM  EDTA) for 44 hours at a temperature of 14°C, field strength of 6 
V/cm using the following parameters: initial switch time, final switch time, and runtime 
for block I, 10 to 60 sec for 18 hours; block II, 30 to 40 sec for 18 hours; and block III,
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50 to 90 sec for 8 hours. Bacteriophage lambda concatemers starting at 48.5 kbp and 
increasing to approximately 1,000 kbp were run as the standard (Promega). Gels were 
stained with 2.0 pg/ml ethidium bromide (EtBr) for 30 minutes, washed in 250 ml 
distilled water for 4 hours, and photographed under UV light using the Gel Doc 2000 
system (Bio-Rad Laboratories, Richmond, CA). Analysis of the PFGE banding patterns 
was performed using BioNumerics (version 2.5) software (Applied Maths, Belgium).
2.5.3 Interpretation of PFGE result.
PFGE was performed as the initial screen to determine whether two isolates 
were genetically the same or different. This was applied to clinical and environmental 
B. pseudomallei isolates. Two strains with identical banding patterns were considered 
to belong to the same clone and no further genotyping was undertaken. Strain pairs in 
which one or more bands differed were evaluated further using an approach based on 
MLST.
2.6 MLST.
2.6.1 Introduction.
MLST schemes and databases have been described for a number of important 
bacterial pathogens including Neisseria meningitidis (152), Streptococcus pneumoniae 
(85) and Staphylococcus aureus (84). An MLST scheme for B. pseudomallei was 
described by Godoy et al. in 2003 (98). MLST identifies variation within fragments of 
seven housekeeping genes that would be predicted to be selectively neutral (152). Each 
B. pseudomallei isolate is defined by a string of seven integers (the allelic profile), 
which correspond to the allele numbers at the seven loci, in the order ace-gltB-gmhD- 
lepA-lipA-narK-ndh. Each unique allelic profile is considered a clone and is assigned a 
ST, which also provides a convenient descriptor for the clone (152;211). An MLST
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database containing the sequences of all alleles, the allelic profiles, and information 
about the Burkholderia isolates, together with analysis tools, is maintained at Imperial 
College (London, United Kingdom) and can be found on the Burkholderia pages of the 
MLST website (www.mlst.net) .
2.6.2 Procedure of MLST of B. pseudomallei. 
2.6.2.1 Preparation of DNA.
To prepare chromosomal DNA, bacterial cells were streaked onto Ashdown’s 
agar and incubated at 37°C overnight. A single colony was inoculated into TSB and 
incubated in air at 37°C overnight. Dense bacterial suspensions were boiled for 15 
minutes. An aliquot of each boiled suspension was checked for the absence of living 
bacteria, and then DNA was extracted from the suspensions using the W izard Genomic 
DNA Purification kit (Promega).
2.6.2.2 Primers.
The primer pairs used to amplify housekeeping gene fragments on chromosome 
1 are shown in table 2-1.
2.6.2.3 PCR.
PCR was performed using a PTC-0200 DNA engine (MJ Research, Cambridge, 
USA). Reactions were carried out in a total volume of 50 p i  Each reaction contained 
IX  reaction buffer, 1.5 mM MgCL, 0.7 pM of each primer, 5 pi of working template 
DNA, 200 pM  of deoxynucleotide triphosphate (dNTP) and 2.5 U of Taq DNA 
polymerase (Promega, USA). Cycling conditions were an initial denaturation at 95°C 
for 4 min followed by 34 cycles of denaturation at 95°C for 30 s, the annealing 
temperature shown in table 2-2 for 30 s, and extension at 72°C for 60 s. The samples
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were then maintained at 72°C for 10 min and cooled to 4°C. The amplification product 
was visualized using 2% agarose gel electrophoresis followed by staining with 
ethidium bromide and visualization using a Gel Doc 2000 system (Bio-Rad 
Laboratories, Richmond, CA).
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2.6.2.4 Clean-up of PCR products.
The amplified DNA fragments (25 pi) were precipitated by mixing with 60 pi of 
20% polyethylene glycol 8000/2.5M NaCl for 1 h at room temperature or 4°C 
overnight. Following centrifugation at 13,000 rpm for 40 min, the supernatant was 
discarded and the pellet was washed with 600 pi of 70% ethanol. The tube was 
centrifuged again as above. The supernatant was then removed and the DNA pellet 
was dried at 37°C for 1 h and resuspended with 10 pi of sterile distilled water.
2.6.2.5 Sequencing.
The DNA fragments on each strand were sequenced using a DYEnamic ET Dye 
Terminator Kit (Amersham) and a M egaBACE 500 sequencer with nested primer pairs 
shown in table 2-2.
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Table 2-2. Primer pairs used for sequencing of amplification products.
Primer name Primer Sequence (5-3')
Nested_aceF GCTCGGCGCTTCTCAAAA
Nested_aceR ATGTCCGTGCCGATGT AGC
Nested _lepAF TTTCGCTTGATCGGCACTG
Nested_lepAR CGAACCACGAATCGATGATGA
Nested_lipAF CATACGGTGTGCGAGGAAGC
Nested_lipAR GCAGGATCTCGTCGGTCGTCT
Nested_narKF GCCACCCGCTCCGCGTGAGC
Nested_narKR AGCCCGCGTTCTGCAACCACA
Nested_ndhF GCAGTTCGTCGCGGACTATCTC
Nested_ndhR GGCGCGGCATGAAGCTC
Nested _gltBF GGCGGCAAGTCGAACACGG
Nested_gltBR GCAGGCGGTTCAGCACGAG
Nested_gmhDF TCGCGCAGGGCACGCAGTT
Nested_gmhDR GTCAGGAACGGCGCGTCGTAG
2.6.3 Interpretation of sequence data.
Seqman™ II software version 6.1 (DNASTAR Inc., USA) was used to analyse 
nucleotide sequences in both forward and reverse strands of the DNA sequence at each 
housekeeping gene. Sequence trace o f both strands were aligned to each other to obtain 
a consensus sequence prior to assignment of allelic number. The allelic numbers of 
previously described loci were assigned using the B. pseudomallei MLST website 
(http://www.mlst.net/) . Sequence that was not in the database was checked by 
resequencing, assigned as a new allele, and deposited in the MLST allele database. 
Following the standard MLST protocol, each allele was assigned a different allele 
number to create an allelic profile (string of seven integers) in the order ace-gltB- 
gmhD-lepA-lipA-narK-ndh. Each unique allelic profile was considered a clone and was 
used to define the ST.
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Chapter 3. Recurrent infection in melioidosis patients in 
northeast Thailand is frequently due to re­
infection rather than relapse.
*
3.1 Chapter content.
Recurrent melioidosis is widely ascribed to relapse caused by a bacterial strain 
that has persisted within a sequestered focus, rather than to re-infection with a different 
strain. This is based on the findings of previous small studies in which isolates from the 
first and second episodes of infection in a given patient usually had the same genotype 
(64;80;105).
The aim of the study was to perform a large, definitive prospective evaluation of 
patients with recurrent melioidosis presenting to Sappasithiprasong Hospital in 
northeast Thailand. This was achieved by:
1. PFGE on all primary and recurrent isolates from 116 patients with recurrent 
melioidosis.
2. Comparing PFGE banding patterns of isolates from primary and recurrent 
infection for each patient, and undertaking a sequence-based approach based 
on MLST for strains with different patterns.
3. Investigating the difference in time to presentation of relapse and re­
infection, and estimating the risk of re-infection for patients who have had a 
primary episode of melioidosis.
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3.2 Materials and Methods.
3.2.1 Patients and bacterial isolates
Patients were prospectively recruited by a study team based at 
Sappasithiprasong Hospital, Ubon Ratchathani, northeast Thailand. Study patients were 
adults (>15 years) with culture-confirmed melioidosis who presented between June 
1986 and July 2004. All patients were followed up until July 2005. Patients with 
suspected melioidosis were actively sought during twice-daily rounds of the medical 
and intensive care wards, together with passive surveillance of surgical and pediatric 
wards via the hospital diagnostic microbiology laboratory. Detailed clinical information 
was recorded, including a past history of culture-proven melioidosis. Blood and throat 
swab samples were collected from all patients for culture. Other specimens (urine, pus, 
and surface swabs of skin lesions) were collected where available. M icrobiology 
specimens were cultured for the presence of B. pseudomallei by standard methods 
(250). Culture-confirmed cases were followed daily until discharge or death. Details of 
history, examination, laboratory results, antimicrobial treatment and clinical course 
were maintained on a password protected computer database. Isolates were stored in 
TSB with 15% glycerol at -80°C. Ethical approval was obtained from the M inistry of 
Public Health, Royal Government of Thailand.
3.2.2 Genotyping.
For all patients with more than one episode o f disease, the first B. pseudomallei 
isolate cultured on the first and subsequent episodes of melioidosis were examined by 
PFGE. Isolates from  primary and recurrent disease for a given patient that were 
different by one or more bands were further examined by MLST. PFGE and MLST 
were performed as described in chapter 2.
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3.2.3 Colony morphology.
Colony morphology was characterised using a published morphotyping 
algorithm (24). Isolates were spread plated to achieve single colonies on Ashdown’s 
agar and incubated for 4 days at 37°C in air. Colony morphology type was compared 
between the first and subsequent cultures for each patient.
3.2.4 Definitions.
Recurrent melioidosis was defined as clinical features of infection in association 
with one or more cultures positive for B. pseudomallei in a patient with a history of one 
or more previous episodes. This included patients who had completed treatment for the 
previous episode, together with patients who had recurrent symptoms while receiving 
oral antibiotics for melioidosis following an initial clinical and microbiological 
response to antibiotic therapy. Time to recurrent disease was measured from the start of 
oral antimicrobial treatment, irrespective of whether the patients received intravenous 
therapy.
Disease relapse and re-infection were defined on the basis of bacterial 
genotyping of isolates from the first and subsequent episode(s). Isolates from the same 
patient with identical banding patterns on PFGE were considered to represent a single 
isolate, and these patients were classified as having relapse. Isolates from the same 
patient that differed by one or more bands were examined further using a screening 
approach based on MLST. This used the assumption that a difference in just one of 
seven MLST loci is sufficient to assign different STs. Two of the seven MLST loci, 
narK  and gmhD, are highly variable within the bacterial population. The sequence of 
narK  was determined first, followed by sequencing of gmhD  for isolate pairs with the 
same allele narK. Isolates from the same patient that differed at one or both of these
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loci were considered to represent re-infection. Those with sequence identity at both 
narK  and gmhD  were further characterized using the remaining five MLST loci to 
define the full ST.
3.2.5 Analysis.
Statistical tests were performed using Stata 9.0 (College Station, Texas, United 
States). Proportions were compared by Chi-square and Fisher’s exact test, as 
appropriate. Continuous variables were compared by the W ilcoxon rank-sum test.
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3.3 Results.
A total of 147 patients presented with 167 episodes of culture-proven recurrent 
melioidosis between June 1986 and July 2004. Of these, five patients had three 
episodes of recurrence, ten patients had two episodes of recurrence and the remainder 
had a single recurrence. Paired isolates were not available for 32 patients. After these 
patients were excluded, isolates from 115 patients with a total of 122 episodes of 
recurrent disease were available for typing. The time to recurrence for 122 episodes 
ranged from 1 to 454 weeks (8.7 years). The median time to recurrence was 39 weeks, 
with an interquartile range (IQR) of 12 to 115 weeks.
3.3.1 The proportion of recurrent disease attributable to relapse and re­
infection.
PFGE banding patterns were identical between the first and subsequent 
infective isolates for 90 o f 122 episodes, including those episodes for five of the six 
patients with more than one recurrence. PFGE banding patterns differed between 
isolate pairs in 32 episodes. This included an episode in one patient with two recurrent 
infections. The strain from  the first recurrence had the same pattern as that of the strain 
from the primary infection, but the second recurrence was caused by an isolate with a 
different banding pattern. The number of bands different between pairs ranged from 1 
to 15 (median, 6 bands; IQR 4 to 7 bands). Sequence analysis of one or both of narK  
and gmhD  indicated that isolates were different for 30 of the 32 episodes. Two isolate 
pairs that were one and four bands different, respectively, on PFGE were identical by 
full sequence typing of all seven loci. Thus, 92 episodes (75%) of recurrence 
represented relapse and 30 episodes (25%) were due to re-infection with a new strain.
There were five isolate pairs that were classified as closely related by PFGE (up 
to three band differences) by the criteria of Tenover et al. (230), o f which four (80%)
were found to be different by sequenced-based typing. O f the 14 pairs classified as 
possibly related (four to six band differences), 13 (93%) were found to be different by 
sequence-based typing. All 13 pairs with greater than six band differences were 
different based on sequence-based typing.
3.3.2 Time to relapse and re-infection.
Time to recurrence differed for episodes due to relapse compared with those due 
to re-infection. Those caused by relapse had a median interval o f 26 weeks (IQR 10-72 
weeks; range 1-454 weeks), while those due to re-infection had a median interval of 
111 weeks (IQR 59-164 weeks; range 1-363 weeks) (PcO.OOl). Time to recurrence and 
the proportion due to relapse and re-infection are illustrated in figure 3-1. A total of 70 
episodes (57%) occurred within 12 months o f the primary infection. Recurrent disease 
was due to relapse in 63 of 70 episodes (90%) that occured within the first year of the 
primary episode, in 13 of the 20 episodes (65%) in the second year after the primary 
episode, and in 16 of 32 episodes (50%) more than 2 years after the primary episode.
3.3.3 Colony morphotype between primary and recurrent strains.
A difference in colony morphotype between primary and recurrent strains was 
uncommon. There were only 12 instances where the colony morphology type was 
different between the isolate pairs associated with primary and recurrent infection. Of 
these, five (42%) represented relapse.
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Figure 3-1. Time to recurrent disease and proportion of cases due to relapse and 
re-infection.
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3.4 Discussion.
In an earlier study performed in our population, isolate pairs from 23 of 25 
patients with recurrent disease had identical or highly similar ribotype patterns, while 
those for two patients were different (80). Follow up was performed for 5 years, and 19 
episodes occurred within the first 12 months. A further study performed in Thailand 
reported different PFGE banding patterns for isolate pairs from 4 of 35 patients with 
recurrent melioidosis (138). In Australia, where recurrent melioidosis was observed in 
27 (13%) patients over a follow-up period of 10 years, the majority of cases (25 of 27) 
were due to relapse as defined by RAPD analysis or PFGE. In these patients, relapse 
occurred between 1 and 27 months (mean 8 months) after the primary presentation, 
while the two re-infections occurred after 14 months and 4.8 years, respectively (64).
In a Malaysian study, four of five recurrences were due to relapse of the original 
infecting strain, as based on ribotyping (240). Our contrasting findings are likely to 
reflect prolonged patient follow-up, with the longest interval between primary infection 
and recurrence being more than 8 years. Use of different typing methods may also be 
important, since ribotyping may be less discriminatory than PFGE (175;242).
The criteria of Tenover et a l  (230) have been widely adopted as the standard 
for the interpretation of DNA macrorestriction banding patterns in 
microepidemiological investigations. DNA macrorestriction patterns that differ by up to 
three bands are interpreted as being closely related, and differences of four to six bands 
are interpreted as possibly related. Use of these criteria in this study without the use of 
further genotyping would have led to the misclassification of four patients with re­
infection into the relapse group and one patient with relapse into the re-infection group.
The predictive power of using colony morphology type as a surrogate for strain 
typing in patients with recurrence was examined here and not found to be useful. The 
presence of different colony morphotypes for isolates associated with primary and
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recurrent infection did not predict re-infection. A study by Chantratita et a l  (24). 
described seven B. pseudomallei colony morphotypes from clinical and environmental 
specimens. However, 93% of isolates from clinical specimens were type I.
In this study, recurrent disease within 12 months was mostly due to relapse of 
the original infecting strain, a finding that is consistent with previous results. However, 
the proportion of recurrent disease due to re-infection increased after this time and after 
2 years, recurrence was related in equal proportions to re-infection and relapse. The 
number of re-infections remained similar for each year of the study. The estimated rate 
of re-infection in people who have had an episode of melioidosis is 5 to 8 per 1,000 
patients per year, which far exceeds the annual incidence in the community for primary 
melioidosis of 4.4 per 100,000 population (222). This illustrates a very high 
susceptibility for re-infection with B. pseudomallei.
This study has important implications for future studies. After intervals 
exceeding 12 months, recurrent disease often represents re-infection rather than 
recrudescence of the original infecting isolate. Studies of oral antibiotic eradication 
therapy for melioidosis that use recurrent disease as a marker of drug efficacy need to 
undertake bacterial typing to accurately distinguish relapse from re-infection, analogous 
to studies o f antimalarials. Future typing studies should consider the use of sequence- 
based verification of the results for isolates that are different on PFGE. Patients with 
previous melioidosis represent a group of individuals who are susceptible to subsequent 
infection. Re-infection following re-exposure to environmental B. pseudomallei is more 
common than had previously been appreciated.
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3.5 Chapter summary.
This study used a robust combination of genotyping techniques to define the 
proportions of recurrent melioidosis due to relapse versus re-infection. Re-infection 
was shown to be a more common cause of recurrent melioidosis than previously 
thought and occurred at the same incidence every year, while relapse was more likely 
to occur within the first year after the primary episode. These findings have important 
implications for the prevention of re-infection in those patients with a history of 
primary melioidosis.
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Chapter 4. Simultaneous infection with more than one strain 
of B. pseudomallei is uncommon in human 
melioidosis. i
4.1 Chapter content.
Recurrent melioidosis is ascribed to re-infection when the genotype of the 
bacterial isolates cultured at the first and subsequent disease episodes are not the same. 
One possible criticism of this approach is that ‘re-infection’ could actually represent 
relapse in the event that the primary infection was caused by simultaneous infection 
with multiple B. pseudomallei strains, followed by chance selection of different strains 
from the two episodes for genotyping. The chance of mistake occurring is based on the 
rate o f polyclonal B. pseudomallei infection. In a previous study of 18 patients 
presenting to a hospital in northeast Thailand between 1992 and 1993 in which 10 to 40 
colonies were picked from primary culture plates, five cases (28%) were shown to have 
infection with more than one genotypic strain using a combination of ribotyping and 
PFGE (175). O f these, four patients had isolates with two genotypic patterns and one 
patient had three. Furthermore, patients with polyclonal infection had more severe 
disease and a poorer outcome.
The aim of this study was to define the rate of polyclonal infection in a large 
group of unselected patients presenting to a hospital in northeast Thailand with their 
first episode of infection. This was achieved as follows:
1. A large, prospective study was conducted to collect appropriate samples 
from patients with suspected melioidosis.
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2. Multiple colonies from multiple samples from a given patient were 
compared using a combination of PFGE and MLST.
3. An analysis was performed to:
i. determine the rate of polyclonal infection, and to
ii. compare the mortality associated with polyclonal versus single clone 
infection.
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4.2 Materials and Methods.
4.2.1 Patients and specimen collection.
Patients were prospectively recruited by a study team based at 
Sappasithiprasong Hospital, Ubon Ratchathani, northeast Thailand, between 28th June 
and 29th September 2006. The study was approved by the Human Research Ethics 
Committee of the Faculty of Tropical Medicine, Mahidol University, Bangkok, 
Thailand. Patients with suspected melioidosis were actively sought during twice-daily 
rounds of the medical and intensive care wards, together with passive surveillance of 
surgical and pediatric wards. Detailed clinical information was recorded, including a 
documented history of culture-proven melioidosis. Multiple samples were taken from 
suspected cases within 72 hours of admission. A 15ml blood sample was taken and 
divided between a BacT/ALERT® FA bottle (BioMerieux, North Carolina) for 
standard culture (5ml), and an IsolatorlO lysis centrifugation tube (Oxoid, Basingstoke, 
Hampshire, UK) (10ml) to allow identification of primary colonies. Samples were 
taken for culture of sputum/tracheal aspirate, throat swab, urine, pus or surface swab 
from wounds and skin lesions, as appropriate or available. Specimens were hand 
carried to the on-site research laboratory at the end of each ward round.
The study was powered to compare the mortality associated with polyclonal 
versus single clone infection. Assuming a polyclonal infection rate of 30% (based on 
the study reported by Pitt et al. (176) which was undertaken in the same population), 
and an overall mortality rate in our melioidosis population of -45% , at least 102 
patients are required to detect a difference in mortality rate of 70% (polyclonal 
infection) and 35% (clonal infection), respectively with 80% power. The number of 
colonies required from each sample was determined; at least ten colonies are needed to 
detect the presence of two strains in a ratio of 1:9 with 85% power. All analyses were 
calculated using Stata 9.0 (College Station, Texas, United States).
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The sample size calculations have been reproduced below:
. sampsi 0.35 0.70, r(0.3) p (0.80)
Estimated sample size for two-sample comparison of proportions
Test Ho: pi = p2, where pi is the proportion in population 1
and p2 is the proportion in population 2
Assumptions:
alpha = 0 . 0500 (two-sided)
power = 0 . 8000
pi = 0.3500
P2 = 0.7000
n2/nl = 0.30
Estimated required sample sizes:
nl = 78
* n2 = 24
. sampsi 0 0.1, onesample p(0.85)
Estimated sample size for one-sample comparison o f .proportion
to hypothesized value
Test Ho: p = 0.0000, where p is the proportion in the population
Assumptions:
alpha = 0.0500 (two-sided)
power = 0.8500
alternative p = 0.1000
Estimated required sample size:
n = 10
i
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4.2.2 Bacterial isolates.
The objective of culture was to achieve single B. pseudomallei colonies on 
primary plates inoculated with material taken directly from the clinical sample. The 
rationale for this was to obtain a true picture of the bacterial population in the primary 
specimen, and to avoid the use of sub-culture in enrichment broth during which one 
strain of B. pseudomallei could outgrow a second.
The 10ml blood sample was collected into a pre-evacuated Isolator 10 tube lysis 
centrifugation blood culture tube (Wampole, UK). The isolatorlO tubes contain SPS, 
saponin and polypropylene glycol in aqueous solution. Isolator tubes were inverted at 
least 10 times after inoculation to ensure adequate mixing, and then transported 
immediately to the on-site microbiology laboratory and centrifuged at 1500 rpm for 30 
minutes. The supernatant (9 ml) was aseptically removed to leave 1 ml of fluid plus 
sediment. The sediment was homogenized using a sterile pipette, and 0.5 ml was spread 
plated onto each o f two plates: horse blood and Ashdown’s selective agar.
Urine was collected into a sterile container and transported immediately to the 
laboratory. Using a sterile calibrated loop, 1 |rl of fresh, unprocessed urine was streaked 
onto one half each of a M acConkey agar plate and an Ashdown’s agar plate which were 
incubated at 37°C for 2 days or 4 days, respectively. The remaining urine sample was 
centrifuged at 3,000 rpm  for 5 min, excess supernatant was removed, and the pellet was 
cultured on one half of an Ashdown’s agar plate.
Samples o f pus and respiratory secretions were serially diluted prior to spread 
plating on Ashdown’s agar plates to obtain single colonies. Throat and wound swabs 
were streaked onto an A shdow n’s agar plate. In addition, these specimens were 
cultured using enrichment broth, as previously described (250). All agar plates were 
examined daily for clinical diagnostic purposes, but were maintained at 37°C in air for 
4 days before colonies were selected for genotyping.
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Colonies o f presumptive B. pseudomallei were initially identified on the basis of 
colony morphotype. This included the characteristic colony morphology (purple, flat, 
dry and wrinkled) together with 6 additional colony morphotypes, as described 
previously (24). Colonies suspected to be B. pseudomallei were tested using the oxidase 
test, and then confirmed using a B. pseudomallei specific latex agglutination test (262). 
Colonies on the primary plate were picked for genotyping when available for a given 
sample; in the event that enrichment broth was positive but primary plates were 
negative, colonies were picked following sub-culture. For samples with a single B. 
pseudomallei colony morphology type present, 10 colonies were picked and saved to 
independent freezer vials. All colonies were picked if less than 10 were present. If 
more than one colony morphology was present, 5 of each were picked to independent 
vials.
4.2.3 Bacterial genotyping.
Genotyping was performed using a combination of PFGE and MLST. All 
colonies were subjected to PFGE using SpeI. Samples from an individual patient were 
run on the same gel and analysed using BioNumerics (version 2.5) software (Applied 
Maths, Belgium). Colonies from a given patient with an identical PFGE banding 
pattern were regarded as genotypically indistinguishable, but isolates with one or more 
bands different were further examined using MLST. PFGE and MLST were performed 
as described in chapter 2.
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4.3 Results.
A total of 215 samples were processed from 133 patients with culture- 
confirmed melioidosis, o f whom 8 (6.0%) were less than 15 years of age, and 4 (3.0%) 
were from cases of recurrent melioidosis. Sample types were blood (n=73), respiratory 
secretions (n=54), urine (n=20), pus (n=18), throat swab (n=26) and wound swab 
(n=24). Mixed B. pseudomallei morphotypes were observed on 18 of 184 (9.8%) 
primary plates. M orphotype I to VII were present in 178 (96.7%), 13 (7.1%), 6 (3.3%), 
4 (2.2%), 6 (3.3%), 7 (3.8%), and 3 (1.6%) specimens, respectively.
A total of 2,058 colonies were examined by PFGE. The median number of 
colonies tested per patient was 10 (IQR 10-20, range 1-70). Two patients had only a 
single colony of B. pseudomallei grown from the Isolator tube, and one patient had 70 
colonies obtained from 7 specimens (blood, urine, respiratory secretions and 4 swabs 
from pustules at forehead, hip and both legs).
A total of 130 patients (97.7%) had colonies with an identical PFGE banding 
pattern, consistent with infection by a single strain of B. pseudomallei. Three patients 
had samples containing colonies with two different PFGE banding patterns, details of 
which are summarized in table 4-1. MLST was performed on a representative of each 
banding pattern from each sample. This demonstrated that two of the three patients 
were each infected with two different strains of B. pseudomallei, confirming polyclonal 
B, pseudomallei infection in 2/133 cases (1.5%; 95%CI, 0.2-5.3%). The third patient 
had multiple samples containing strains that differed by 2 bands on PFGE, which on 
MLST was shown to be a single clone (table 4-1). The two patients with polyclonal 
infection survived to hospital discharge, completed 20 weeks of oral antibiotic 
treatment and were well on 3 month follow up.
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4.4 Discussion.
This large prospective study of unselected patients with melioidosis has 
demonstrated that primary infection with more that one strain of B. pseudomallei is 
very uncommon. These findings differ considerably from those o f Pitt et al. (176). The 
reason for this is not clear; laboratory contamination leading to more than one strain in 
a sample or freezer vial is unlikely since the PFGE patterns were not shared between 
isolates associated with mixed infection, although this does* not rule out the possibility. 
Case and sample selection could lead to variable results between the two studies. Pitt et 
al. (176) reported mixed infection involving samples collected during the months of 
August or September of 1992 or 1993, compared with this study when recruitment was 
performed of consecutive patients between June and September of 2006. The 
distribution of sample types was also different, with 14/18 (78%) samples in the study 
by Pitt et al. representing blood cultures compared with 73/215 (34%) in this study. The 
possibility that in vivo selection of a biologically successful clone occurs following 
mixed infection has not been excluded, but this seems unlikely given the approach 
taken here of culturing all available sample types in a given patient.
It is proposed that the re-infection rate of 25% defined for patients with 
recurrent infection described in chapter 3 represents a true measure, and that patients 
who survive to hospital discharge following a first episode require counseling regarding 
the risk and strategies for avoidance o f further, independent episodes o f melioidosis.
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4.5 Chapter summary.
Simultaneous infection with more than one strain of Burkholderia pseudomallei 
is uncommon in human melioidosis. A difference in disease severity was not observed 
between patients with single clone infection and polyclonal infection, although this 
calculation was underpowered as a result of the small number of patients with mixed 
strain infection.
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Chapter 5. Genetic diversity of B. pseudomallei in the 
environment.
5.1 Chapter content.
It is possible that ‘relapse’ could actually represent re-infection in the event that 
re-infection is caused by a B. pseudomallei clone that is indistinguishable from that 
caused the primary episode. The probability of this occurring is based on the genetic 
diversity of B. pseudomallei, and in particular the diversity of strain present in the 
environment. Individuals are repeatedly exposed during their agricultural work to a 
defined, often small area of soil.
The aim o f this study was to evaluate the genetic diversity and population 
structure of B. pseudomallei. This was achieved by:
1. Defining the genetic population of B. pseudomallei in a defined area of land 
in northeast Thailand.
2. Evaluating the genetic population of B. pseudomallei in Thailand.
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5.2 Materials and Methods.
5.2.1 Study site.
Soil samples were collected during September 2005 (the rainy season) from an 
area o f disused land measuring 237.5 m 2 (23.75 m x 10 m) situated to one side of road 
231 in Amphoe Meung, at a distance o f 8 km  northeast of Sappasithiprasong Hospital, 
Ubon Ratchathani, northeast Thailand. This is a rural rice growing region, and road 
traffic is light. Cattle range through the area, although none were present on the land 
during sampling. The soil type was sandy loam, and was wet under foot but not 
flooded. The vegetation was low lying scrub and the area showed no signs of 
cultivation. The site included a single concrete electricity pole. A brick wall formed one 
boundary, running parallel to and distal from the road.
Five people undertook sampling over a 2 day period of intermittent rain. The 
site was initially divided into a grid system using string and wooden stakes, in which 5 
x 20 spots were plotted 2.5 m apart on the vertical axis, and 1.25 m apart on the 
horizontal axis. The spot was referenced by letters of the alphabet (A to E for horizontal 
rows as viewed with back against the road, row A lying closest to road) and 
numerically (1 to 20, moving across from left to right on vertical axis). Each spot is 
hereafter termed a ‘sampling point’ and the specific site defined by its grid reference.
5.2.2 Soil sampling.
A hole was dug with a clean spade to a depth of approximately 30 centimetres.
A clean plastic bag was placed on weighing scales and a sample of soil (100 grams) 
was removed from the base of the hole and placed into the bag. Each soil sample was 
labeled using pre-prepared stickers denoting the grid reference number. The bag was 
closed and stored out of direct sunlight at ambient temperature until transported to the 
laboratory where it was processed on the same day. The utensils used for sampling
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were cleaned between each use by rinsing with bottled water to remove visible debris, 
followed by cleaning with 70% ethanol and air drying.
5.2.3 Soil culture and B. pseudomallei identification.
Soil samples were batch processed at the end of each collection day. 100 ml of 
sterile water was added to each bag, mixed well and left overnight to sediment. The 
upper layer of water was then transferred by plastic pipette to a sterile plastic container. 
Four aliquots of 100 \i\ were spread plated onto each of 4 Ashdown’s selective agar 
plates. A further 1 ml of the soil water sample was added to 9 ml of selective 
enrichment broth consisting of threonine-basal salt plus colistin (TBSS-C50 broth).
This was incubated at 40°C in air for 48 h, after which 10 pil of surface liquid was plated 
onto a second Ashdown's agar plate which was incubated and observed as before. Agar 
plates were incubated at 40°C in air and visually inspected daily for 4 days. Colonies of 
B. pseudomallei were initially identified on the basis of colony morphotype. This 
included the characteristic colony morphology (purple, flat, dry and wrinkled) together 
with 6 additional colony morphotypes, as described previously (24). Colonies suspected 
to be B. pseudomallei were tested using the oxidase test, and positive colonies 
confirmed as B. pseudom allei using the specific latex agglutination test (262).
5.2.4 Colonies and genotyping of B. pseudomallei.
Genotyping of B. pseudomallei was performed for 3 sampling points (grid 
reference A 11, D10 and E4). These were selected at random from sampling points that 
gave at least 200 B. pseudom allei colonies on the primary Ashdown’s agar plates. For 
each sampling spot selected, all primary colonies were picked to purity and subjected to 
PFGE using SpeI. Analysis of PFGE banding patterns for the 200 colonies at each of 
the three sampling points was performed using BioNumerics (version 2.5) software
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(Applied Maths, Belgium). For the purposes of this study, interpretation was defined so 
as to be highly discriminatory. Isolates with identical PFGE banding patterns were 
regarded as genotypically indistinguishable, but isolates with one or more bands 
different were defined as a putatively different and given a different banding pattern 
number. One bacterial representative of each banding pattern type was further 
examined using MLST. PFGE and MLST were performed as described in chapter 2.
5.2.5 Measures of genetic diversity.
5.2.5.1 Genetic diversity of B. pseudomallei in disused land.
Genetic diversity of B. pseudomallei within a given sampling point was defined 
using Simpson’s index o f diversity. This describes the probability that two randomly 
selected bacterial cells within a sampling point will be different genotypes; 0 indicates 
no diversity and 1 indicates infinite diversity. Confidence intervals for Simpson’s index 
were calculated as described previously (103). Genetic diversity between two sampling 
points was measured using the M orisita index of similarity. This ranges from 0 to 1; 0 
indicates that no genotypes are shared between the two sampling points, and 1 indicates 
complete identity. Further analysis was performed to examine whether the genetic 
distance between isolates within a given sample was significantly different from that 
expected if all isolates were randomly distributed between three sites. The number of 
different alleles (0->7) was determined for all 19900 pairwise comparisons of the 200 
colonies (strains) at each of the three sampling points. This was compared to mean 
values calculated from 100 random samples, each of 200 strains, drawn with 
replacement from the combined data set of 600 strains (all three sample sites).
Statistical significance was gauged by calculating the 0.01, 0.05 and 0.95 and 0.99 
percentiles from the resampled data. All analyses were calculated using Stata 9.0
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(College Station, Texas, United States), except the random resampling procedure which 
used a Perl script.
5.2.5.2 Genetic diversity of B. pseudomallei in Thailand.
ST data were downloaded from the MLST database 
(http://bpseudomallei.mlst.net) for all isolates listed as having originated from 
Thailand. Diversity was defined based on the number of isolates per ST, and total 
number of STs resolved for this population.
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5.3 Results.
5.3.1 Positivity of B. pseudomallei culture from soil sampled from disused land.
A total of 80 out of the 100 sampling points were culture positive for B. 
pseudom allei, of which 77 were positive from both direct plating onto Ashdown’s agar 
and selective enrichment broth, and 3 were positive from selective enrichment broth 
culture alone (figure 5-1.) B. thailandensis was not detected.
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5.3.2 Genotyping of B. pseudomallei isolated from soil.
The genetic variability o f B. pseudomallei was defined and compared within 
and between sampling points by genotyping 200 colonies at each of three positive 
points (A l 1, DIO and E4, see figure 5-1). PFGE of 600 individual primary colonies 
revealed 12 PFGE banding pattern types. MLST of a single random isolate of each of 
the 12 PFGE types revealed 9 STs (table 5-1). Figure 5-2 shows the PFGE banding 
patterns.
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Figure 5-2. Twelve d ifferen t P F G E  banding  p a tte rn s  identified fo r soil isolates.
PFGE type M 1 2 3  4 5 6 7 3
I____________ I I____________ I
9 10 11 12 M
E4 DIO A l l
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Table 5-1. Results of PFGE and MLST for soil isolates.
PFGE
ST
MLST profile
Type ace gltB gmhD lepA lipA narK ndh
1 ST 424 4 12 10 4 8 3 1
2 ST 177 1 1 4 3 1 3 1
3 ST 176 3 1 4 1 1 3
4 ST 185 1 4 2 2 1 4 1
5 ST 33 1 4 12 1 1 2 1
6, 11, 12 ST 60 3 1 ' 12 1 1 3 1
7 ST 163 3 2 2 ' 1 1 4 1
8, 10 ST 93 1 1 2 1 1 4 1
9 ST 304 1 1 5 1 1 4 1
104
5.3.3 Genetic diversity of B. pseudomallei in soil.
Table 5-2 shows the breakdown of STs within each of the three sampling points. 
DIO and E4 each contained four STs and A l l  contained three STs. Although the 
distance between the 3 sampling points was low (7.6, 7.9 and 13.3 meters for A l 1-D10, 
D10-E4, and A l 1-E4, respectively), only two STs were present in more than one 
sampling point (E4/D10; ST176, and D10/A 11; ST60); no STs were common to E4 and 
A l l ,  and no STs were detected in all three points. This strong separation between sites 
is reflected in low values of the M orisita index (table 5-2). Furthermore, each site was 
characterized by the following predominant genotypes, each o f which was restricted to 
a single site: ST93 in A l 1 (87%), ST163 in DIO (51.5%), and ST185 in E4 (70%). 
Simpson’s index of diversity ranged from 0.24-0.65 (table 5-2).
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Table 5-2. Genotyping results for 200 colonies of B. pseudomallei from each of 
three independent sampling points.
ST
Sampling points
E4 D10 A l l
ST 424 38 (19%)
ST 177 12 (6%)
ST 176 10 (5%) 29 (14.5%)
ST 185 140 (70%)
ST 33 50 (25%)
ST 60 18 (9%) 9 (4.5%)
ST 163 103 (51.5%)
ST 93 174 (87%)
ST 304 17 ,(8.5% )
Sim pson’s index of
diversity (95% Cl) 0.47 (0.40-0.54) 0.65 (0.60-0.69) 0.24 (0.16-0.31)
M orisita Index of
similarity
- compared to E4 - 0.02 0.00
- compared to D10 - - 0.01
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The finding of very limited overlap between the sites was further examined by 
comparing the average pairwise distance (in terms of allelic mismatches) between 
isolates within each site to that expected if the three sample sites were combined as a 
single population. Figure 5.3 shows the proportion of all 19,900 ((200 * 199) /  2) 
pairwise comparisons showing 0, 1, 2 ... 7 allelic mismatches for each of the seven 
MLST loci for 200 colonies (strains) examined at each of three independent sampling 
points. This was compared to randomised data derived from the mean values for 100 
random samples of 200 strains resampled with replacement from the combined data set 
of 600 strains from all three sites. All three sampling sites showed a significantly 
greater proportion of identical pairs (i.e. the same ST) than the randomised data 
(PcO.Ol), which is consistent with localized clonal expansion. For two of the three 
sampling sites, there was no significant difference in the proportion of related but non­
identical STs (i.e. those differing at a single locus) compared with the randomised data. 
The exception was site A l l  where a significantly higher number of pairwise 
comparisons (P<0.01) corresponded to a single MLST locus difference; ST304 is a 
single locus variant of the predominant clone ST93, being variant at gmhD. 
Comparison of the two gmhD  alleles (allele 2 for ST93 and allele 5 for ST304) 
indicated two base differences (C—>T position 118, and T —>C position 327). The other 
ST at A l l  is ST60; this differs at three loci from both ST93 and ST304, accounting for 
the small peak at three mismatches in the A l 1 plot.
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Figure 5-3. Graph of the proportion of all pairwise comparisons showing allelic 
mismatches for each of 200 primary colonies (strains) examined at three 
independent sampling points.
0 .8*1
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0 .2 -
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0 2 3 61 4 5 7
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Number of allelic mismatches
th  th* Error bars are based on the 5 and 95 percentiles of the 100 random samples. 
No pw comparisons (real or trial data) differ at all seven sites since the locus 
ndh is monomorphic (invariant).
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Comparison of PFGE and MLST results demonstrated that two STs contained 
strains with variable PFGE banding pattern types. ST93 contained strains with two 
PFGE types (types 8 and 10), which were 12 bands different. This ST was only found 
in sampling site A 11, in which the proportion of each banding pattern was 172/174 
(99%) for type 8, and 2/174 (1%) for type 10. ST60 contained strains with three PFGE 
types (types 6, 11 and 12). The difference in banding patterns between these three was 
6 bands (PFGE types 6 versus 11), 1 band (PFGE types 6 versus 12), and 2 bands 
(PFGE types 11 versus 12). ST60 was recovered from two sampling points (A 11 and 
DIO, 7.6 m apart). The proportion o f each PFGE type identified at the two sampling 
points was as follows: sampling point A l l  (total 9 colonies), type 11 (8 colonies) and 
type 12 (1 colony); sampling point DIO, all 18 colonies were type 6. The number of 
PFGE bands different between the single locus variants ST304 (type 9) and ST93 
(types 8 and 10) were: type 9 vs. type 8, 18 bands; type 9 vs. type 10, 10 bands.
5.3.4 Genetic diversity of B. pseudomalleiin Thailand.
MLST revealed a high level of diversity for B. pseudom allei isolates listed in 
the public MLST database as having been isolated in Thailand from both clinical and 
environmental samples. There were 285 different STs for the 565 B. pseudomallei 
isolates in the database, as of 7th August 2007. Of these, 198 STs (69%) are represented 
by single isolates, and 87 STs (31%) included more than 1 isolate (range, 2 to 21). This 
high diversity was observed for both clinical isolates and environmental isolates when 
considered separately (figure 5-4). Simpson’s index of diversity was 0.92 (95%CI,
0.92-0.93) for clinical isolates and 0.96 (95%CI, 0.95-0.96) for environmental isolates.
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Figure 5-4. Bar graph representing the number of isolates per ST found in clinical 
isolates, environmental isolates, and isolates with undetermined source originating 
from Thailand.
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5.4 Discussion.
This study has demonstrated marked geographic structuring of B. pseudomallei 
genotypes in disused land. A high genetic diversity was also demonstrated for all Thai 
B. pseudomallei isolates listed in the MLST database. Simpson’s index of diversity of 
around 0.95 indicates that the probability that a given individual will develop primary 
infection and re-infection with isolates sharing the same ST is extremely remote. This 
may become more likely if host genetic susceptibility were to select for specific 
bacterial clones, but there is no evidence that this is the case for melioidosis. Extreme 
genetic diversity over a small area of the environment suggests that an individual who 
repeatedly works within a restricted area of land is nonetheless exposed to a genetically 
diverse B. pseudomallei population. Taken together, these findings support the validity 
of genotyping in order to delineate relapse and re-infection in patients with recurrent 
melioidosis.
The dramatic differences in genotype frequency over such small distances are 
striking, but difficult to interpret. One explanation is that the numerically dominant ST 
at each sampling point represents a strain with superior biological fitness compared 
with STs present as a minority of the population. This could relate to factors such as 
soil type or pH, or competition with other microbial species. This would assume that 
adjacent foci of soil have variable microenvironments; it seems unlikely that nearby 
sampling points within a confined area of disused land would differ so dramatically.
An alternative possibility is that of local competition between clones of B. 
pseudomallei. Soil may be subjected to events such as flooding which provides an 
opportunity for a given clone to migrate and become established within a specific 
focus. Once the clone has reached a certain threshold frequency, it could repel invaders 
either by the production of microbicides, through phage to which they are themselves 
resistant, or via other killing mechanisms. The presence of a clone as a minority
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population could represent the ability of this strain to survive at a lower level, or could 
represent the boundary o f a point of predominance in an adjacent point or focus.
This study also provides evidence for microevolution of B. pseudomallei in soil. 
PFGE is a more sensitive marker of genetic change than MLST, since alterations in 
banding pattern arise due to genetic events that alter the presence or absence of 
restriction sites for the enzyme used, while housekeeping genes are more highly 
conserved. Two of the nine STs contained strains with variable PFGE banding pattern 
types. These changes may represent microevolution within the sampling site rather than 
importation of the same ST with a different banding pattern, based on the low 
probability of co-localization o f two strains with the same ST on a background of 
marked genetic diversity of the overall population. This is consistent with the finding 
that genomic islands constitute -6%  of the B. pseudomallei K96243 genome (109). 
Furthermore, comparison of the whole genome sequence of B. pseudomallei and B. 
mallei indicates the capacity for genomic rearrangement and gene loss by two species 
that are highly related by MLST (165). These findings are consistent with a dynamic 
genome that is evolving through the movement of genomic islands and rearrangements 
such as inversions, indels and the movement of insertion sequences.
The co-existence of a single locus variant (ST304) of ST93 in a single soil 
sample can be explained by in situ microevolution or by a chance association. ST93 
and ST304 have both been isolated previously in northeast Thailand. Our unit 
recovered ST93 from the environment in 1990, 1998 and 1999, each from different 
sampling sites situated along road 212 which runs northwest from the town of Ubon 
Ratchathani. The MLST database (www.mlst.net) contains a fourth ST93 isolate that 
was associated with human disease in Thailand in 1998. Our unit have also recovered 
ST304 from two different patients with melioidosis presenting to a hospital in northeast 
Thailand in 1999. However, the marked genetic diversity of B. pseudomallei suggests
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that the probability of these two STs co-existing by chance in the same soil sample is 
extremely low.
An important potential confounder of this study is that the proportion of each 
ST is obtained after the soil sample has been prepared and then grown using rich media. 
This raises the possibility that some STs are more adapted to survival or growth after 
the addition of distilled water during sample preparation, or in moving to the surface 
water layer which is then removed for culture. It is also possible that some STs are 
more likely to grow on laboratory media than others, and that some STs are viable but 
non-culturable under the conditions used. Resolution of these issues will require the 
direct and immediate application of molecular tools to soil samples, and comparison of 
genotypes with those obtained using conventional culture and existing soil preparation 
methods.
These findings have important implications for future genotyping studies. Soil 
sampling at a single location will fail to identify the genotypes present even a few 
meters away. Furthermore, the dominance o f a single ST at a given site indicates that 
extra sampling effort is required to detect rare genotypes which may be present. For 
example, the characterization of approximately 50 colonies from any single site would 
provide an 85% probability of detecting a genotype present at the site at a frequency of 
2%. This is based on the exact 95% binomial confidence interval for ST60 at sampling 
point A l l ,  which was present in the lowest number.
These findings also have implications for future studies in which PCR is 
performed directly on soil extracts to detect B. pseudomallei. The amplification product 
may be mixed, and DNA from strains present at low copy number is unlikely to 
undergo amplification. Thus, PCR represents acceptable technology if  the objective is 
to determine B. pseudomallei presence or absence, but would be inappropriate if PCR is 
used as the basis for subsequent genotyping unless multiple independent amplicons are
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evaluated. The problem this then poses is how a genotyping scheme could be devised 
based on the sequence of a single PCR product.
This study has investigated B. pseudomallei in soil taken from an area of 
disused land. This is in contrast to many previous studies in Thailand which were 
conducted in rice paddies. The basis for this choice was to examine an environment 
free o f external influences such as chemical fertilizers and pesticides, together with the 
effect of ploughing, planting, burning of rice stubble and the presence of rice plants. 
However, most disease is probably acquired in rice paddies; further studies are required 
to compare and contrast the findings reported here with those from a rice paddy in the 
same region.
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5.5 Chapter summary.
A study was performed to determine the presence and genotypes of B. 
pseudomallei in soil sampled from disused land in northeast Thailand. B. pseudomallei 
was present on direct culture o f 77/100 sampling points. Genotyping of 200 primary 
plate colonies from 3 independent sampling points was performed using a combination 
of PFGE and MLST. Twelve PFGE types and 9 STs were identified, the majority of 
which were present at only a single sampling point. Despite the proximity of the 
sampling points, each o f the three samples was characterized by the localized 
expansion of a single clone, corresponding to STs 185, 163 and 93. High genetic 
diversity of B. pseudom allei was also observed for isolates originating from Thailand 
that are listed in the public M LST database. Extreme structuring of genotypic 
frequency in soil suggests that the probability of an individual becoming re-infected 
with the same clone as that causing the primary episode is extremely remote. This 
supports the use o f genotyping to differentiate between relapse and re-infection in 
patients presenting with recurrent melioidosis.
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Chapter 6. Risk factors for recurrent melioidosis in 
northeast Thailand.
6.1 Chapter content.
Risk factors for recurrence have been defined previously and include severity of 
initial disease, antimicrobial drugs used and treatment duration (27;29;42;184). These 
studies have largely treated recurrence as a homogenous condition, with cases being 
assumed to have resulted from relapse of a persistent focus of infection.
The aim o f this study was to re-evaluate relapse and re-infection separately to 
define their individual risk factors. This was achieved by evaluating a cohort of patients 
with culture-confirmed melioidosis who presented to Sappasithiprasong Hospital 
during a 19-year period to define risk factors for relapse and re-infection. Specifically:
1. Clinical factors and antimicrobial treatment in patients with recurrent 
disease due to relapse confirmed by bacterial genotyping were compared 
using a time-varying Cox proportional hazard model to determine specific 
risk factors.
2. The cohort was re-evaluated to determine risk factors for re-infection.
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6.2 Materials and Methods.
6.2.1 Patients.
Study patients were adults (>15 years) with culture-confirmed melioidosis who 
presented to Sappasithiprasong Hospital, Ubon Ratchathani, northeast Thailand 
between June 1986 and July 2004. All patients were followed up until July 2005. 
Patients with suspected melioidosis were identified and managed as described in 
chapter 3. Recurrent infection was detected from the medical history and via cross- 
referencing within the patient database. Ethical permission was obtained from the 
Ethical and Scientific review sub-committee of the Thai M inistry of Public Health.
6.2.2 Definitions.
Predisposing factors for melioidosis defined here were diabetes mellitus, renal 
calculi, chronic renal failure, thalassemia, connective tissue disease requiring steroid 
therapy or other immunosuppressive treatment, alcoholism, chronic liver disease, 
malignancy and traumatic injury. Diabetes mellitus was defined as either pre-existing, a 
new diagnosis as defined by the American Diabetes Association criteria (2), or acute 
hyperglycaemia (random plasm a glucose >11.1 mmol/L) after recovery requiring 
hypoglycaemic drug treatment. Impaired renal function was defined as an estimated 
glomerular filtration rate below 60 mL/min/1.73 m 2 during admission. Glomerular 
filtration rate was estimated using an abbreviated form o f the M odification of Diet in 
Renal Disease study equation (4). Melioidosis was classified as bacteraemic (blood 
culture positive plus a single or no identifiable focus of infection), disseminated (blood 
culture positive plus >1 non-contiguous foci of infection), localized (single focus of 
infection and blood culture negative), or multifocal (>1 non-contiguous foci of 
infection and blood culture negative). Recurrent melioidosis was defined as described 
in chapter 3.
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6.2.3 Treatment.
Standard of care throughout the study period was in-patient intravenous 
antimicrobial therapy followed by a prolonged course of oral drugs. Many patients 
were included in prospective studies o f antimicrobial chemotherapy and as a result the 
regimens used varied over time.
In 1986, the recommended parenteral treatment was a four-drug combination of 
chloramphenicol, trimethoprim, sulphamethoxazole and doxycycline. A trial conducted 
between September 1986 and July 1988 comparing this regimen to intravenous 
ceftazidime (255), resulted in a change in first-line parenteral treatment to ceftazidime. 
A trial conducted between January 1989 and October 1992 compared intravenous 
ceftazidime and intravenous AMC (224), and a trial conducted between August 1994 
and November 1997 compared intravenous ceftazidime and imipenem (201). Patients 
outside clinical trials were treated with ceftazidime. Parenteral therapy was changed if 
the clinician considered that treatment was failing, or if there was a significant adverse 
reaction to the drug. Oral treatment was substituted when the patient showed sufficient 
clinical improvement. Timing o f the switch to oral antimicrobial drugs was based on 
clinical judgm ent plus local guidelines that parenteral therapy should be given for at 
least 7 days (1986 to 1993), or for at least 10 days (1994 onwards).
Standard oral treatment was either a combination of chloramphenicol, TMP- 
SMX and doxycycline ( ‘four-drug regim en’), TMP-SMX plus doxycycline ( ‘three-drug 
regim en’), or AMC. A study was conducted between June 1986 and August 1989 of the 
efficacy of oral AMC (221), and an open randomised trial comparing oral AMC and the 
four-drug regimen was conducted between June 1989 and October 1992 (184). Oral 
fluoroquinolones were evaluated as a single agent between June 1991 and M arch 1995 
(30). An open randomised trial conducted between October 1994 and August 1997 
compared oral doxycycline alone and the four-drug regimen (27), and a trial conducted
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between August 1997 and July 1998 compared oral ciprofloxacin plus azithromycin 
with the three-drug regimen (42). A trial comparing the four-drug versus three-drug 
regimen was conducted between July 1998 and October 2002 (26). Between 1986 and 
1989, guidelines for oral therapy were to use the four-drug regimen for at least 6 weeks. 
In June 1989, the duration of oral therapy was extended to 12-20 weeks. Side effects 
were common with the four and three drug regimens, and AMC was used during the 
study period as an alternative or following drug intolerance, and was first-line treatment 
for children or pregnant women.
6.2.4 Follow-up and outcome.
Patients who survived to discharge entered a programme of lifelong follow up 
by a senior clinician and collaborator working at Sappasithiprasong Hospital (W. 
Chaowagul). Following discharge, patients were seen every 2-4 weeks until completion 
of oral treatment, and every 3-12 months thereafter. Patients who failed to attend clinic 
were assumed to have ceased their medication at last follow up. Follow up data to July 
2005 was included in this study.
6.2.5 Data analysis.
All analyses were performed using the statistical software Stata 9.0 (College 
Station, Texas, United States). The analysis was predominantly episode-based, 
although some of the univariate descriptive statistics presented are patient-based. 
Analyses were based on time-to-event with time measured from the start of oral 
antimicrobial treatment, irrespective of whether they received intravenous therapy. 
Events were defined as the clinical onset of culture-confirmed recurrent infection, death 
from other causes, or last follow-up. Periods of parenteral treatment for clinical 
recurrences were treated as gaps in observation. W hen a patient with culture-confirmed
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recurrent melioidosis survived and started oral treatment, this was treated for analysis 
purposes as a new episode of observation. The observation time began at zero for each 
recurrent episode, and the analysis was stratified by the number of previous genotype- 
proven relapses (as opposed to re-infections). The primary analysis aimed to determine 
the risk factors associated with relapse. This analysis was censored for re-infection, 
death from causes other than culture-confirmed melioidosis, and loss to follow-up. The 
secondary analysis was performed to assess risk factors for re-infection, and censored 
for relapse, death from other causes, and loss to follow-up. Non-informative censoring 
was assumed, as the reasons for censoring were considered unlikely to be associated 
with either relapse or re-infection.
The 28 independent variables (potential risk factors) considered included patient 
demographics, presence of pre-morbid conditions, body sites involved in the infective 
process, and antimicrobial treatment given. Log-rank tests and univariate stratified Cox 
regression analysis were used to compare the association between each independent 
variable and the two dependent variables. Time-to-event outcome was assessed using 
Kaplan-Meier survival analysis, and the W ilcoxon test was used for variable 
comparison when appropriate. Stratified multivariate Cox proportional hazard models 
were used to adjust for interactions between factors for relapse and re-infection, 
respectively. Recurrence on treatment and duration of oral treatment were also modeled 
as time varying covariates. The final Cox proportional hazard models were developed 
using purposeful selection and significant continuous variables analyzed using the 
methods described by Hosmer and Lemeshow (114).
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6.3 Results.
6.3.1 Patients.
A total of 2,517 patients with a first episode of culture-confirmed melioidosis 
were recruited during the 19-year study period, of which 1,229 (49%) died during 
admission or were taken home to die. Of those who survived, 921 (72%) patients 
presented to follow up clinic at least once and were eligible for inclusion in this 
analysis. Patient age for the 921 patients ranged from 15 to 80 years (median 48 years; 
IQR 38 to 58 years), and 60% were males. One or more predisposing factors were 
documented for 697 of 921 (76%) patients. Diabetes mellitus was the most common 
underlying condition (524/921 (57%)). Impaired renal function was present in 572/921 
(62%) patients. The majority of patients were admitted and given parenteral treatment, 
with only 15 (2%) being treated in the out-patient department with oral therapy alone. 
Localized disease was the most common presentation (48%), followed in frequency by 
bacteraemic (23%), disseminated (18%) and multifocal (11%) presentations. The 
median number of body sites involved was 1 (IQR 1 to 2; range 0 to 6). The four-drug 
regimen, AMC regimen and the three-drug regimen were initially prescribed for oral 
eradication therapy in 266 (29%,), 248 (27%), and 196 (21%) patients, respectively.
6.3.2 Follow-up and outcome.
Total duration of follow-up was 29,750 patient-months. Median duration of oral 
treatment with any regimen was 18 weeks (IQR 9 to 21 weeks; range 0-244 weeks). 
Median duration o f follow-up for patients without recurrence was 72 weeks (IQR 25 to 
186 weeks; range 1 to 908 weeks). A total of 167 episodes of culture-confirmed 
recurrent melioidosis occurred in 147 of 921 (16%) patients. O f these, 122 (73%) 
paired strains were available for genotyping, while one or more B. pseudomallei 
isolates were not available for typing for 32 patients with recurrent infection. These 32
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patients were excluded from further analysis since it was not possible to distinguish 
accurately between relapse and re-infection, giving a total of 889 patients who went 
forward for further analysis. There was no significant difference in demographics and 
clinical presentation between the group of relapse patients without paired samples and 
those for whom paired samples were available (data not shown). It was considered 
unlikely that excluding these patients would bias determination of factors associated 
with relapse and re-infection, though it may lead to underestimates of the size of the 
associated absolute risks or hazards.
Of the 122 recurrent melioidosis cases, 92 (75%) cases in 86 patients had 
relapse as defined by genotyping. Four of these patients relapsed twice and 1 patient 
relapsed three times. The other 30 (25%) episodes were re-infections as defined by 
genotyping. One patient had re-infection after completing treatment for an episode of 
relapse. Median time to relapse was 26 weeks (IQR 10 to 72 weeks; range 1 to 454 
weeks), while median time to re-infection was 111 weeks (IQR 59 to 164 weeks; range 
1 to 363 weeks) (P<0.001).
A total of 85 people died during the follow up period. O f these, 29 patients died 
as a result of recurrent melioidosis; 19 were in the relapse group (1 died during a 
second relapse), and 10 were in the re-infection group. The mortality rate associated 
with the first recurrent episode (relapse and re-infection combined) was 24% (28/115 
patients; 95%CI, 17%-33%). This was lower than the mortality rate of 49% (95%CI, 
47%-51%) for primary melioidosis in the study cases. There was no significant 
difference in mortality between the relapse and re-infection groups (21% versus 34%; 
P=0.14). Causes of death in the remaining 56 patients were: clinically suspected 
culture-negative melioidosis (19), hepatobiliary malignancy (3), chronic renal disease 
(2), leukaemia (2), liver cirrhosis (2), gut obstruction (1), heart disease (1), ischaemic 
stroke (1), nosocomial infection (1), HIV infection (1) and unknown cause (23).
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6.3.3 Risk factors for relapse.
On univariate analysis, patients with renal calculi and those with a positive 
blood or urine culture had a greater risk of relapse (table 6-1). The distribution of 
infection affected risk o f relapse; using localized melioidosis as the comparator, 
patients with multifocal, bacteraemic and disseminated melioidosis were more likely to 
relapse. Individual organ involvement was not associated with outcome.
In an analysis o f the effects of each parenteral antibiotic, choice of drug did not 
affect the risk of relapse (table 6-2). Furthermore, the duration of effective intravenous 
therapy (classed as ceftazidime, a carbapenem drug or AMC) was not related to risk of 
subsequent relapse.
The first oral drug regimen used was associated with rate of relapse (P<0.001), 
but not re-infection (P=0.07) (table 6-2). A Kaplan-M eier graph for time to relapse was 
constructed to compare different first oral antimicrobial regimens (figure 6-1). Relapse 
was not significantly different between the standard three-drug and four-drug regimens 
(P=0.42, W ilcoxon test), but AMC and other regimens (fluoroquinolone-based 
regimens, doxycycline alone, and TMP-SMX alone) were associated with an increased 
risk o f relapse. AMC was significantly associated with relapse compared to the 
standard three-drug and four-drug regimen (P=0.01 & P=0.001, respectively), and 
negatively associated with relapse compared to the group containing all other regimens 
(P=0.003). Duration of standard oral treatment was highly negatively associated with 
risk o f relapse (HR 0.71, P<0.001); the hazard ratio decreasing by 29% for every 4- 
week increase in duration of standard oral treatment (four drug regimen, three drug 
regimen or AMC).
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Figure 6-1. Kaplan-Meier plot illustrating time to relapse associated with first oral 
antimicrobial treatment regimen for the treatment of melioidosis.
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0.00
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weeks
 Four-drug regimen (TMP-SMX, doxycyline and chloramphenicol)
 Three-drug regimen(TMP-SMX and doxycyline)
 Amoxicillin-clavulanic acid
 Other regimens (fluoroquinolone-based, doxycycline alone
and TMP-SMX alone regimens)
All variables were entered and developed into the multivariate model (table 6- 
3). Patients having a positive blood culture or multifocal distribution had a higher risk 
of relapse. AMC and an ‘ineffective’ oral treatment regimen (fluoroquinolone-based 
regimens and doxycycline alone) were associated with relapse. The effect of duration 
of standard oral treatment'was evaluated by stratifying treatment duration into blocks 
with one-month increments (<8 weeks, >8-12 weeks, >12-16 weeks, >16-20 weeks, 
and >20 weeks) (figure 6-2). Each block of treatment longer than 8 weeks compared to 
<8 week treatment was highly negatively associated with relapse. Risk of relapse was 
not significantly different between each block of treatment longer than 8 weeks (data 
not shown). The relationship between duration of treatment and risk of relapse was not 
linear, and the lowest hazard ratio was duration of treatment was between 12 to 16 
weeks.
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Table 6-3. Determinants of relapse in the final Cox proportional hazard model.
Prognostic factor
Hazard Ratio 
(95%CI)
P  value
Multifocal melioidosis 2.05 (1.09-3.87) 0.03
Blood culture positive 1.84(1.17-2.89) 0.01
First oral treatment regimen:
Four-drug and three-drug regim ensa 
Amoxycillin-clavulanic acid 
Other regimens b
1.0
2.09(1.14-3.83)
3.16(1.63-6.15)
0.02
0.001
Duration of treatment with standard regim ensc 
(month)
0.87 (0.75-1.01) 0.06
Relapse on treatment
On a standard oral reg im enc 
On other regimen b or Off treatment
1.0
2.31 (1.11-4.82)
0.03
a 4 drugs, TM P-SMX, doxycyline and chloramphenicol; 3 drugs, TMP-SMX and 
doxycyline
b fluoroquinolone-based regimen, doxycycline alone and TMP-SMX alone 
c TMP-SMX, doxycycline and chloramphenicol, TM P-SM X and doxycyline, or AMC
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Figure 6-2. Estimate of hazard ratios and 95 % CIs of duration of standard oral 
antimicrobial treatment (TMP-SMX, doxycyline and chloramphenicol, TMP-SMX 
and doxycyline, or AMC) versus relapse.
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* A duration of <8 weeks was used as the comparator for other treatment 
durations, analyzed using incremental blocks of 4 weeks (>8-12 weeks, >12-16 
weeks and >16-20 weeks) together with >20 weeks. Patients treated for longer 
than 40 weeks were excluded for the purposes of figure clarity (1 relapse patient 
and 32 non-relapse patients). There was no significant difference in results on 
comparison of data when the >40 week group were included or excluded (data 
not shown).
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6.3.4 Risk factors for re-infection.
No factors were associated with re-infection on univariate and multivariate 
analyses. The incidence of re-infection in this study population after survival of a first 
episode of melioidosis was 1,280 per 100,000 person-years (95%CI, 895-1,831). This 
may be an underestimate because of the omission o f re-infection cases in whom 
genotyping of paired samples was not possible, but is still orders of magnitude higher 
than previously published figures for the general population in this province of 4.4 per
100,000 person-years (95%CI, 3.8-5.0) (222).
To evaluate the possibility of bias introduced by the exclusion of recurrent 
patients who did not have paired B. pseudomallei isolates for typing, re-analysis was 
performed to compare results from data sets that either included or censored this group 
one month before recurrence occurred. There was no significant difference in outcomes 
for relapse and re-infection groups (data not shown).
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6.4 Discussion.
The risk factors associated with relapse in this study are similar to those in the 
published literature (27;29;42;184). The finding that intravenous antimicrobial 
treatment was not associated with risk of relapse contrasts with a previous report of a 
higher rate of recurrence following a parenteral four-drug regimen or AMC compared 
with ceftazidime (29). However, the results presented here for parenteral AMC should 
be interpreted with caution since its use was relatively low. The current 
recommendation that parenteral treatment should be given for at least 10 days remains 
unchanged.
Choice and duration of oral antimicrobial therapy were the most important 
determinants of relapse. Analysis of the optimal treatment duration indicated that the 
lowest hazard ratio was associated with between 12 to 16 weeks of oral treatment. This 
is consistent with previous findings that treatment for less than 8 weeks or less than 12 
weeks was associated with recurrence (26;29). Analysis of patients receiving oral 
treatment for >16 weeks may have been confounded by the presence of a greater 
proportion of patients in this group with complicated or severe disease associated with 
a higher risk of treatment failure and relapse. The suggested minimum duration of oral 
treatment o f 12 to 20 weeks remains unchanged, with the actual duration being guided 
by clinical progression.
This study provides evidence for the efficacy of TM P-SM X plus doxycyline for 
oral therapy; this is consistent with an earlier report that the addition of 
chloramphenicol is not necessary (26). AMC was associated with an increased risk of 
relapse, but remains an alternative for patients with intolerance to the three-drug 
regimen, and continues to be used for the treatment of children and pregnant women in 
Thailand. Other regimens such as fluoroquinolone-based regimens and doxycycline 
alone were associated with a high risk of relapse, an unsurprising finding given their
lack of efficacy in previous studies (27;30;42). The number of patients who started oral 
treatment with TMP-SMX alone was low (n=3) and underpowered for analysis as a 
stand-alone group. For practical purposes, these patients were grouped into ‘other 
regim ens’, and this study is not able to draw any conclusions regarding efficacy.
The definition of recurrent disease captured 5 patients that had been discharged 
< 2 weeks previously following treatment of a primary episode. These patients had 
deteriorated clinically after a clinical response, but interpretation of culture positivity in 
such cases is a grey area since culture can remain positive for B. pseudomallei for 
several weeks, and ‘relapse’ in these cases may reflect clinical fluctuations in the 
course of recovery from the primary episode.
This study failed to identify risk factors for re-infection; this may relate to a lack 
of statistical power, or the fact that relevant variables were not included. The higher 
rate of re-infection compared to the rate of primary infection in northeast Thailand 
indicates that risk factors do exist. These may relate to specific host factors or high-risk 
activities including occupation. Further study is required to elucidate these and 
determine whether preventive strategies could be implemented.
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6.5 Chapter summary.
This study highlights clinical factors associated with an increased likelihood of 
relapse, and provides evidence for optimal oral antimicrobial therapy. There was no 
difference in acute outcome between relapse and re-infection groups. Multivariate 
analyses identified choice and duration of oral antimicrobial therapy as the most 
important determinants of relapse, followed by positive blood culture and multifocal 
distribution. Patients treated with an appropriate oral antibiotic regimen for 12 to 16 
weeks had a 90% decreased risk of relapse compared with patients who were treated <
8 weeks. TM P-SMX plus doxycycline was an effective oral therapy. No risk factors for 
re-infection were identified. However, the rate of re-infection in patients who recovered 
from primary melioidosis was very high, indicating that prevention of re-infection is 
necessary.
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Chapter 7. A simple scoring system to differentitate
between relapse and re-infection in patients with 
recurrent melioidosis.
7.1 Chapter content.
Determining the cause o f recurrent melioidosis is an important clinical 
distinction with implications for investigation and management, but the overwhelming 
majority of medical centres treating patients with melioidosis in Asia do not have the 
facilities to perform bacterial genotyping, and recurrence is usually considered to be 
synonymous with relapse. In addition, isolates from the primary episode may not be 
available if  bacterial strains are not routinely frozen or if the patient had a primary 
episode of infection at another hospital.
The aim of this study was to define factors associated with relapse or re­
infection, and to use these to develop a simple scoring system for use in resource- 
limited settings to predict the most probable cause of recurrent melioidosis. This was 
achieved by:
1. Comparing clinical factors between relapse and re-infection to determine 
possible predictive factors for either cause of recurrent melioidosis.
2. Developing a scoring system to differentiate between relapse and re­
infection based on a multivariate logistic model with relapse/re-infection as 
the independent variable.
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7.2 Materials and Methods.
7.2.1 Patients.
Study patients were adults (>15 years) with culture-confirmed recurrent 
melioidosis who presented to Sappasithiprasong Hospital, Ubon Ratchathani, northeast 
Thailand between June 1986 and September 2005. Patients with suspected melioidosis 
were identified and investigated as described in chapter 3. Patients who survived the 
primary episode recieved oral eradicative treatment and were followed up monthly for 
one year, then yearly thereafter. Oral antimicrobial regimens were as described 
elsewhere (chapter 6). Patients with recurrence were identified from the history, patient 
notes and by cross-reference with our database. Follow up data in this study was to 
February 2007.
7.2.2 Antimicrobial susceptibility testing.
All B. pseudomallei isolates were tested for susceptibility to the antimicrobial 
drugs used to treat melioidosis (meropenem, ceftazidime, AMC, doxycycline and 
trimethoprim/sulfamethoxazole (TMP-SMX)). This was performed using the disk 
diffusion method with the exception of TMP-SMX, which was assessed using the Etest 
(AB Biodisk, Solna, Sweden) (263). All isolates defined as intermediate or resistant to 
a given drug by disk diffusion were tested further using the Etest. Interpretative 
standards were based on CLSI guidelines, which lists resistance for ceftazidime, AMC, 
doxycycline and TM P-SM X as >32 mg/L, >32 mg/L, >16 mg/1 and >4/76 mg/L, 
respectively, and intermediate resistance as 16 mg/L, 16 mg/L, 8 mg/1, and N/A, 
respectively (57).
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7.2.3 Definitions.
Diabetes mellitus and impaired renal function were defined as described in 
chapter 6. Hypotension was defined as a systolic blood pressure less than 90 mmHg, 
acute renal failure as a 50% decrease in the baseline-calculated GFR (203), and 
respiratory failure as the need for mechanical ventilation.
7.2.4 Statistical analysis.
All analyses were performed using the statistical software Stata 9.0 (College 
Station, Texas, United States). A scoring system to differentiate between relapse and 
re-infection was developed. The variables considered included patient demographics, 
presence of pre-morbid conditions, body sites involved in the primary and recurrent 
episode, antimicrobial treatment given for the primary episode, patterns of 
antimicrobial resistance for the primary and recurrent isolates and duration between 
primary and recurrent episode. Comparison between relapse and re-infection of each 
variable was performed using Fisher’s exact test or the W ilcoxon-M ann-W hitney test, 
as appropriate. All variables associated with relapse/re-infection at P<0.20 were 
included as independent variables in a multivariate logistic model with relapse/re­
infection as the dependent variable. Variables were removed one at a time from the 
model if the p-value as determined by the likelihood ratio test was >0.05, least 
significant variable first. To double check that no significantly predictive variables 
were removed during this process, each de-selected variable was tested in turn with the 
final model and reintroduced into the model if  P<0.05 (113). Variables in the final 
model were used to construct a scoring system. Each statistically significant continuous 
variable was plotted against the predicted value and the LOWESS (locally weighted 
least squares) smoothing function was plotted. The shape of the curve on the 
distribution of values was used to suggest ranges for each variable. To assign points to
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ranges, dummy variables were created for each range, and all such dummy variables 
were used in a multiple logistic regression analysis. The coefficient for each variable 
was multiplied by 10 and rounded off to the nearest integer. A total score was 
formulated by the sum of points from each variable for each patient, and the results 
plotted on a receiver-operator characteristic (ROC) curve. The Hosmer-Lemeshow 
goodness-of-fit test was used to evaluate the regression model, along with analysis of 
the area under the ROC curve.
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7.3 Results.
7.3.1 Patients.
A total of 2,804 adult patients with culture-confirmed melioidosis were seen 
during the 19-year study period. Of these, 1,401 (50%) adult patients died during 
admission. Of the adults who survived, 1,001 (71%) patients presented to follow up 
clinic at least once. M edian duration of follow-up for patients without recurrence was 
65 weeks (IQR 22-179 weeks; range 1-954 weeks). A total of 194 episodes of culture- 
confirmed recurrent melioidosis occurred in 170 (17%) patients. Of these, 148 (76%) 
strains paired from the primary and recurrent episode were available for genotyping 
from 141 patients. Bacterial genotyping had been performed previously for 122 
episodes in 115 patients as described in chapter 3, and genotyping of the remainder was 
performed during this study.
7.3.2 Bacterial genotyping.
Ninety-eight (66%) of the 148 recurrent melioidosis episodes in 92 (65%) of 
141 patients represented relapse as defined by genotyping. Four of these patients 
relapsed twice and 1 patient relapsed three times. The other 50 episodes in 49 (35%) 
patients were caused by re-infection. One patient had re-infection after completing 
treatment for an episode of relapse. For the purposes of this study, only the 141 first 
episodes of recurrent melioidosis (92 relapse and 49 re-infection) were analyzed.
7.3.3 Antimicrobial susceptibility.
All B. pseudomallei isolates associated with the primary episode of recurrent 
infection were susceptible to ceftazidime, AMC and doxycycline, while 21/141 (15%) 
were resistant to TMP-SMX. All isolates associated with recurrence were susceptible to 
ceftazidime. Strains associated with re-infection were resistant to AMC, doxycycline
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and TMP-SMX in 2% (1/49), 2% (1/49) and 16% (8/49) of cases, respectively. Strains 
associated with relapse were resistant to AMC, doxycycline and TM P-SMX in 1% 
(1/92), 1% (1/92) and 12% (11/92), respectively. The two patients with relapse 
associated with the development of bacterial resistance to AMC (MIC from 2 to 16 
mg/L) or doxycycline (1 to 96 mg/L) received antimicrobial treatment with the 
respective agent for at least 8 weeks prior to relapse.
7.3.4 Specific factors associated with relapse and re-infection.
The majority of patients with re-infection presented in the rainy season, while 
patients with relapse presented throughout the calendar year (P=0.002, figure 7-1). 
Demographic characteristics and clinical features are shown in table 7-1. Sex and age 
were comparable between the two groups. Diabetes mellitus was the most common 
underlying condition in both relapse and re-infection. Impaired renal function was 
present in 42 (46%) of 92 patients with relapse and 32 of 49 (65%) patients with re­
infection (P =0.03). Distribution of infection and organ involvement on primary 
infection and at time of recurrence was not different between patients with relapse and 
re-infection. There was no difference in severity o f infection between relapse and re­
infection as defined by hypotension, acute renal failure or respiratory failure (p>0.05 in 
all cases). Death occurred in 17 (18%) patients with relapse and 13 (27%) patients with 
re-infection (P=0.29).
On univariate analysis, the duration of oral antibiotic treatment for the primary 
episode was significantly shorter for patients with relapse than re-infection (P<0.001). 
The median time to relapse was also significantly shorter than time to re-infection (6 
months versus 24 months, P<0.001) (figure 7-2). On multivariate analysis, significant 
independent predictors of re-infection were the presence of a low GFR on admission of 
recurrent episode and calendar period o f presentation (rainy season). Short duration of
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oral antimicrobial treatment for first episode of infection, and an interval between the 
primary infection and recurrence of less than one year were predictive for relapse (table 
7-2). The area under the ROC curve for this model was 0.81 (95% Cl: 0.74-0.89), and 
the Hosmer-Lemeshow goodness-of-fit test was not significant for lack of fit (P=0.16).
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Table 7-1. Demographic characteristics and clinical features of patients presenting 
with relapse and re-infection.
Variable Relapse
(n=92)
Re-infection
(n=49)
P value
Men, No. (%) 59 (64%) 29 (59%) 0.59
Age (yr) at recurrence, median (IQR) 49 (42-58) 47 (39-55) 0.25
Diabetes mellitus 58 (63%) 27 (55%) 0.37
Estimated G FR a on admission with 60 (35-88) 42 (27-60) 0.02
recurrence, median (IQR)
Site(s) involved during recurrent
infection
Bacteraemia 43 (47%) 28 (57%) 0.29
Pneumonia 27 (29%) 17 (35%) 0.57
Liver abscess 17 (18%) 9 (18%) 1.00
Splenic abscess 14(15% ) 7 (14%) 1.00
Skin or soft tissue infection 31 (34%) 16 (33%) 1.00
Arthritis 13 (14%) 8 (16%) 0.81
Osteomyelitis 7 (8%) 1 (2%) 0.26
Complications of recurrent infection
Hypotension 15 (16%) 11 (22%) 0.37
Acute renal failure 22 (24%) 17 (35%) 0.24
Respiratory failure 10(11% ) 7 (14%) 0.59
First oral antibiotic regimen for 
primary episode
Three-drug reg im enb 9 (10%) 6(12% ) 0.14
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Four-drug regim en0 
Amoxycillin-clavulanic acid 
Other regimen d
10(11% ) 
23 (25%) 
50 (54%)
12 (24%) 
12 (24%) 
19 (39%)
Duration o f oral treatment for primary 
episode, weeks, median (IQR)
1 (0-5) 16(0-21) <0.001
Recurrence in rainy season (June to 
November)
44 (48%) 37 (76%) 0.002
Time to recurrence (months) median 
(IQR)
6(2-17) 24 (9-45) <0.001
Death attributable to recurrent 
melioidosis
17 (18%) 13 (27%) 0.29
a mL/min per 1.73 m2,
b Trimethoprim-sulfamethoxazole and doxycycline,
0 Trimethoprim-sulfamethoxazole, doxycycline, and chloramphenicol, 
d Fluoroquinolone-based regimen, doxycycline alone, and trimethoprim- 
sulfamethoxazole alone.
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Table 7-2. Multivariable predictors of re-infection among patients with recurrent
melioidosis
Predictor OR (95% Cl) P Value
Time to recurrent melioidosis more than one year 
Presentation in rainy season (June to November) 
Duration of oral treatment receiveda 
Estimated GFR on admission with recurrence 
(mL/min per 1.73 m2) b
3.56 (1.53-8.27) 
3.31 (1.37-8.00) 
1.04(1.01-1.08) 
0.83 (0.72-0.95)
0.003
0.008
0.012
0.007
a The OR is for a week increase of treatment with effective oral treatment regimens, 
including TMP-SMX and doxycycline based regimens and AMC regimen 
b The OR is for a 10 mL/min per 1.73 m 2 increase
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Figure 7-1. Calendar month of presentation for patients with relapse or re­
infection.
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Figure 7-2. Interval between primary episode and recurrent infection for patients 
with relapse or reinfection.
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7.3.5 Scoring system to determine cause of recurrent melioidosis.
A scoring system was generated based on a combination of predictors of re­
infection or relapse in the multivariate model (figure 7-3). Factors associated with re­
infection (presentation during the rainy season or with reduced renal function) were 
given a positive score. An arbitrary distinction was made between an estimated GFR on 
admission of < 30, 30 to < 60, 60 to < 90, and > 90 mL/min per 1.73 m2. Factors 
associated with relapse were given a negative score. The interval between the primary 
infection and recurrence was considered as being within one year, or greater than one 
year from the start of oral antimicrobial therapy. Oral antimicrobial treatment of the 
primary infection was grouped into periods of < 8 weeks, 8 to < 16 weeks, 16 to 20 
weeks and > 20 weeks. A non-linear association was found between the duration of oral 
treatment received and predictive value of relapse. A score was reached based on the 
accumulation of points from the four variables. The area under the ROC curve for the 
re-infection score was 0.84 (95%CI, 0.77-0.91).
The predictive ability of the risk index model for relapse and re-infection is 
depicted in figure 7-4. A score of less than -5 correctly identified relapse in 75 of 89 
patients (84%) in this group, whereas a score of more than 0 correctly identified re­
infection in 29 of 40 patients (73%). A score ranging from -5 to 0 was classified as 
indeterminate; a total of 12 patients (9%) fell into this group.
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Figure 7-3. Predictors of re-infection and relapse for patients with recurrent
melioidosis.
Predictor Points
Presentation in rainy season (Jun to Nov) -------------- 1 10
Estimated GFR on admission (mL/min per 1.73 m 2)
<30 --------------------
30 to < 60 -------------- 1 10
60 to < 90 -------1 5
>90 0
Time to recurrent melioidosis < 1 year -12 I-----------
Duration of oral treatment received
< 8 weeks -24 I----------
8 to < 16 weeks -9 I------
16 to 20 weeks 0
> 20 weeks -8 I—
-30 -20 -10 () 10
\
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Figure 7-4. Predictive ability of the risk index model for relapse and re-infection 
within range of point < -25, -25 to < -15, -15 to < -5, -5 to 0, >0 to 5, >5 to 15, and > 
15, respectively.
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7.4 Discussion
Determining the cause of recurrence in a range of infectious diseases is very 
important as relapse and re-infection have different implications for disease control and 
clinical management. Relapse reflects treatment failure, in which antimicrobial 
regimen, elimination of a persistent focus and drug adherence are the main concerns. 
Re-infection on the other hand involves exogenous infection with a new strain, and has 
implications for disease prevention and health education strategies. In clinical practice, 
if all recurrent infections are generally assumed to be relapses, inferior secondary 
treatment may be used based on the assumption that the recurrence is a failure of 
previously prescribed first-line treatment. Use of second-line drugs is associated with 
an increased rate of relapse (chapter 6), and exposes patients with re-infection to a 
higher risk o f relapse from this new episode than would otherwise be the case. In 
addition, the prevention of re-infection remains ignored.
For many infectious diseases, the clinical differentiation of relapse from re­
infection is difficult or impossible, and genotyping has been generally been used for 
this purpose. Examples include tuberculosis (45;141), malaria (121; 168), 
Staphylococcus aureus bacteraemia (92), pneumococcal bacteraemia (91), infective 
endocarditis (52) and nosocomial infections (190;227). However, genotyping 
techniques are generally not widely available for tropical infections in endemic areas.
In addition, isolates are rarely stored outside of the research setting, making it 
impossible to compare isolates associated with the primary and recurrent disease.
Clinical differences between re-infection and relapse have been proposed for 
Lyme disease, although a scoring system was not developed (162). Scoring systems 
have been described for the prediction of outcome from melioidosis (37), and to predict 
a number o f other events including atrial fibrillation after cardiac surgery (155). This 
scoring system is the first clinically-based scoring system to differentiate between
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relapse and re-infection in any infectious disease, and may act as a paradigm for other 
infections. It is fast and simple to use, necessitating data on only four easy to assess 
factors. This scoring index can be used where bacterial genotyping is unavailable, 
which covers the majority of melioidosis-endemic regions. The factors associated with 
recurrent melioidosis are similar to those reported for recurrence o f Lyme disease 
(relapse after previous inadequate treatment and within a short period, and re-infection 
during the ‘high’ season when ticks increase in numbers) (162) and may represent 
features that could be used for other infectious diseases.
Using genotyping to compare primary and recurrent isolates to distinguish 
between relapse or re-infection could be confounded by two major factors. First, ‘re­
infection’ could actually represent relapse in the event that primary infection was 
caused by simultaneous infection with more than one bacterial strain, and different 
strains were picked by chance for genotyping (176). However, infection with more than 
one strain o f B. pseudomallei occurs in less than 2% of case (chapter 4). Second, 
‘relapse’ could actually represent re-infection in the event that re-infection was caused 
by a different strain that was nonetheless indistinguishable on genotyping from the first 
infecting strain. The probability of this occurring is unlikely, however, since the B. 
pseudomallei population in the environment is extremely diverse (chapter 5).
The finding of a non-linear association between duration of oral treatment 
received for the primary episode and predictive value of relapse is consistent with a 
previous analysis; patients treated for more than 20 weeks may have more complicated 
or severe disease associated with a higher risk of treatment failure and relapse (chapter 
6). Bacteraemia and multifocal infection during the primary episode have been 
identified as risk factors for relapse compared to patients who did not have relapse 
(chapter 6); however, these two variables were not significantly different between the 
relapse and re-infection groups. This scoring system was developed in Thailand, and
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validation in other settings such as northern Australia is required to determine its 
applicability elsewhere.
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7.5 Chapter summary
This study highlights clinical factors associated with presentation of relapse and 
re-infection, and describes the development of a simple scoring system to define the 
probable cause of recurrent melioidosis. Duration of oral antimicrobial treatment 
received for the primary episode, time between the primary episode and recurrence, 
presentation of recurrence during the dry or rainy season and GFR at recurrence were 
independent predictors o f relapse or re-infection. Factors associated with re-infection 
were given a positive score and factors associated with relapse a negative score. An 
overall score of less than -5 correctly identified relapse in 75 of 89 patients (84%), 
whereas a score >0 correctly identified re-infection in 29 of 40 patients (73%). The 
scoring index had good discriminative power, with an area under the receiver operating 
characteristic curve of 0.84 (95%CI, 0.77-0.91). This simple scoring index can be used 
to predict the most probable cause of recurrent melioidosis, providing timely and 
important bedside information. This could prove invaluable in settings where 
genotyping is not available and bacterial isolates are rarely stored. The findings have 
the potential to improve clinical care at zero cost, and could act as a paradigm for other 
recurrent infections.
154
Chapter 8. Concluding comments.
1. Genotyping was used to compare isolates pairs cultured during primary and 
recurrent melioidosis in 115 patients to determine the proportion of patients who have a 
subsequent episode of infection due to failure to eradicate the organism (relapse) versus 
those who become re-infected with a new strain. Three quarters of cases were shown to 
be due to relapse, and one quarter was related to re-infection. The incidence of re­
infection in the study population after survival of a first episode of melioidosis was 
significantly higher than previously published figures for the general population in this 
area, a finding that has important implications for prevention. This increase in risk may 
be due to host genetic or acquired factors. On-going studies in our laboratory are 
evaluating host genetic susceptibility for melioidosis, in which genetic polymorphisms 
relating to innate and acquired immunity are being defined in melioidosis cases and 
controls. The events leading up to relapse may also relate to bacterial factors. Whole 
genome sequencing of two pairs of primary and relapse strains is being conducted by 
TIGR to determine the nature of genetic changes that accrue in vivo over time. A larger 
number of strain pairs could also be examined using variable number tandem repeats 
(VNTR) to determine the extent to which microevolutionary changes occur in the 
human host. An important, as yet unanswered question is where and how B. 
pseudom allei persists in the human body. B. pseudomallei are taken up by phagocytic 
cells, and it is possible that this results in bacteria becoming shielded from the immune 
response and the effect of antibiotics. M ultinucleate giant cell formation has been noted 
to occur during human disease, and it is possible that bacteria become adapted to persist 
in this potentially complex cellular milieu. Unpublished data from our laboratory 
indicates that relapse often affects the same body sites as those implicated in the 
prim ary episode. This could be interpreted to mean that the organism persists at the
155
infected site(s) and leads to relapse affecting the same organ. However, involvement of 
the same organ has also been observed for patients with re-infection. This suggests that 
host susceptibility may play a major role in the body sites involved in both relapse and 
re-infection, either because seeding of bacteria is more likely in previously damaged 
tissue, or because host genetic traits increase the probability for a specific pattern of 
organ involvement and disease manifestations. M ouse models and host genetic studies 
in patients with recurrent infection may ultimately provide answers to these questions.
2. Genotyping o f isolates from primary and recurrent melioidosis could be 
prone to error if mixed infection was common during primary infection, and different 
strains were picked by chance during the first and subsequent episode for genotyping. 
In this case, relapse would be mistakenly classified as re-infection. A large prospective 
study of 133 patients with culture-proven melioidosis was performed to determine the 
rate of infection with more than one strain of B. pseudomallei. This proved to be rare, 
and so does not represent a significant source of error.
3. Assigning re-infection based on the finding that the isolate cultured during 
primary and recurrent melioidosis was the same genotype could be prone to error if  the 
population genetic structure of B. pseudomallei in the environment, where infection is 
acquired, was clonally restricted. In this case, re-infection could be mistakenly 
misclassified as relapse. A study was conducted to define the genetic diversity of B. 
pseudomallei in soil in an area of disused land in NE Thailand. This demonstrated that 
environmental B. pseudomallei are highly genetically diverse, and it is highly 
improbably that a patient would be re-infected by chance with the same strain. An on­
going study is now evaluating the genetic diversity of B. pseudomallei in a nearby rice 
field, to reflect the type o f setting where the majority of infections are probably
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acquired. Preliminary data indicate that marked genetic diversity is also observed, 
despite the effects of ploughing, fertilizers and pesticides.
4. Understanding the risk factors for relapse and re-infection could result in 
strategies to reduce the risk of these events. Multivariate analyses identified choice and 
duration of oral antimicrobial therapy as the most important determinants of relapse, 
followed by positive blood culture and multifocal distribution. This has important 
implications for patient care. Compliance with oral medication taken for the treatment 
of melioidosis is likely to be crucial, in addition to appropriate prescribing practices by 
medical staff. None of the factors considered were found to be risk factors for re­
infection, but targeting behavioural factors that lead to repeated exposure to the 
organism is a realistic option for reducing risk in this group. General guidelines to 
reduce exposure have been recommended to farmers, who are the highest at-risk group. 
However, rice farming involves wading in mud together with exposure of the arms, and 
wearing full-length boots and gloves may prove uncomfortable during the course of a 
working day in the tropics. Alternative strategies are an increase in the use of 
mechanical implements to reduce exposure time, and eradication of B. pseudomallei 
from the soil. The former requires analysis of cost-effectiveness and government 
support as it is expensive. For the latter, studies of the efficacy of biocontrol are being 
conducted. The ultimate in prevention would be the development and implementation 
of a vaccine programme. However, this may prove to be more complex than for other 
organisms. Most healthy individuals living in melioidosis-endemic areas in Thailand 
develop antibodies to B. pseudomallei but these are not protective in later life. Since B. 
pseudomallei is an intracellular pathogen the development of cell-mediated immunity 
(CMI) is likely to be important, and it is not clear whether healthy exposed people also 
develop CMI that goes on to fail in later life. A vaccine would need to protect the most
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vulnerable individuals with co-morbidites such as diabetes and chronic kidney disease, 
and this may represent a significant challenge. Testing such a vaccine would also be a 
challenge, since the identification of surrogate markers of protection such as an 
antibody response or CMI may not be sufficient to demonstrate efficacy, and large 
studies would be required that were sufficiently powered to show a reduction in disease 
incidence. Further important insights may be gained by studying the immune responses 
of patients who do and do not relapse or become reinfected following a primary episode 
of melioidosis.
5. The majority of hospitals in melioidosis-endemic regions do not have access 
to genotyping facilities. A simple scoring system was devised that utilises readily 
available information to determine the most probable cause for recurrence. This 
approach m ay be applicable to other infectious diseases in which recurrent infection 
occurs following a primary episode, including tuberculosis (45; 141), malaria (121; 168), 
Staphylococcus aureus bacteraemia (92), pneumococcal bacteraemia (91), infective 
endocarditis (52) and nosocomial infections (190;227). This is complicated by the fact 
that simultaneous infection with more than one genotype is not uncommon in malaria 
and tuberculosis. In addition, a genotyping scheme for malaria has yet to be evaluated 
and standardized. Specific risk factors for relapse and re-infection in these infectious 
diseases have not been fully evaluated although this could prove useful for patient 
management. As genotyping is not available in resource-limited settings and isolates 
are rarely stored outside of the research setting, a simple scoring system to determine 
the cause o f recurrent infection in other infectious diseases could have widespread 
applicability.
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Appendix. Solutions and buffers for PFGE.
1 M Tris (pH 8.0)
121.1 g of Tris base
Dilute to 1,000 ml with distilled water and adjust pH with HC1 to 8.0 
0.5 M  EDTA (pH 8.0)
j
186.1 g of EDTA
Dilute to 1,000 ml with distilled water and adjust pH with NaOH to 8.0
SE buffer (75 mM NaCl and 25 mM EDTA, pH 7.5)
4.38 g of NaCl
50 ml of 0.5 M EDTA (pH 8.0)
Dilute to 1,000 ml with distilled water and adjust pH to 7.5 
Note: The SE buffer is used to make the plug agarose.
Lysis buffer (0.1% sodium dodecyl sulfate and 25 mM EDTA, pH 8.0)
1 g of sodium dodecyl sulfacte 
50 ml of 0.5 M EDTA (pH 8.0)
Dilute to 1,000 ml with distilled water and adjust pH to 8.0
TE buffer (10 mM Tris and 10 mM  EDTA)
10 ml of 1M  Tris (pH 8.0)
20 ml of 0.5 M EDTA (pH 8.0)
Dilute to 1,000 ml with distilled water.
Note: The TE Buffer is used to wash lysed PFGE plugs.
5x TBE buffer (450 mM Tris, 450 mM boric acid, and 10 mM EDTA)
54 g of Tris base
27.5 g of boric acid
20 ml of 0.5 M EDTA (pH 8.0)
Dilute to 1,000 ml with distilled water
0.5x TBE buffer (45 mM Tris, 45 mM boric acid, and 1 mM EDTA)
100 ml of 5x TBE buffer 
900 ml of distilled water 
Note: The 0.5x TBE buffer is used for gel electrophoresis running buffer.
